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SUMMARY 
 
Skeletal muscle inflammation plays a critical role in bridging early muscle injury responses and 
timely muscle injury recovery (Yang and Hu, 2018). In this study, we investigated the functional 
role of the sphingolipid-metabolizing enzyme Acid Sphingomyelinase (A-SMase) in the 
pathophysiology of acute and chronic muscle damage in order to elucidate its role in the 
establishment of inflammation and in the subsequent muscle regeneration process so that this 
protein may be proposed as possible therapeutic target. A-SMase is a critical mediator of cell 
signaling since it is able to generate ceramide from the membrane lipid sphingomyelin thus 
modulating membrane fluidity, which is determinant in triggering many cellular processes. Several 
recent studies report the strong relation between high levels of A-SMase expression and 
inflammatory-associated disorders (Schissel et al., 1998; Devlin et al., 2008; Garcia-Ruiz et al., 
2015).  
In this study, we found that A-SMase expression increases upon induced-acute muscle damage 
suggesting its involvement in skeletal muscle inflammation. We also demonstrated the importance 
of A-SMase in regulating the muscle regeneration process following acute muscle damage. Our 
results showed that A-SMase deficiency leads to an increase of muscle satellite cells, essential for 
skeletal muscle regeneration, soon after injury, accompanied by a higher number of regenerating 
myofibers within the injured site. Moreover, two important muscle transcription factors, MyoD and 
Myogenin, responsible for a correct regeneration were much higher in the absence of A-SMase 
suggesting that muscle regeneration is accelerated without the hydrolase. In addition, IGF-1, a 
potent enhancer of tissue regeneration, showed much higher expression levels in absence of A-
SMase, consistently with our finding that A-SMase deficiency accelerates the regeneration process. 
Furthermore, we provide the first evidence of a novel role of A-SMase in regulating macrophage 
subsets during muscle regeneration demonstrating that A-SMase is able to regulate the polarization 
of macrophages towards an inflammatory M1 phenotype since its absence leads to an impairment in 
the expression of M1 macrophage markers.  
Noteworthy, investigating the role of A-SMase in mdx mice, a mouse model of Duchenne Muscular 
Dystrophy (DMD), we found an up-regulation of A-SMase in expression and activity in muscles of 
these mice, that implies its involvement in the pathogenesis of DMD with a particular effect on 
inflammation. Several studies demonstrated a predominant role of inflammation in the pathogenesis 
of DMD (Villalta et al., 2009; Radley et al., 2008). Of notice, we observed that the increase of A-
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SMase in mdx mice paralleled with the increase of muscle inflammatory state. This finding has been  
further corroborated by the use of the anti-inflammatory drug Naproxcinod that reduced 
inflammation in mdx muscle and at the same time significantly decreased A-SMase expression and 
activity.  
Altogether, our findings open new vistas in the identification of a new potential pharmacological 
target, A-SMase, in the development and regulation of skeletal muscle inflammation and 
regeneration process by raising the possibility that the modulation of A-SMase expression levels 
could bring therapeutic benefits not only in DMD pathology but also in various muscle-wasting 
diseases.  
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L’infiammazione del muscolo scheletrico rappresenta la prima risposta protettiva conseguente ad un 
danno muscolare e svolge un ruolo fondamentale nel recupero funzionale del muscolo (Yang and 
Hu, 2018). In questo studio, abbiamo investigato il ruolo dell’enzima-idrolasi Sfingomielinasi 
Acida (A-SMase) nella patofisiologia del danno muscolare acuto e cronico con lo scopo di 
comprendere al meglio il suo ruolo funzionale nell’insorgenza del processo infiammatorio e nella 
successiva fase di rigenerazione muscolare affinché possa essere considerato come possibile 
bersaglio terapeutico. L’A-SMase è un mediatore critico nella segnalazione cellulare; la sua 
capacità di generare ceramide a partire da un importante lipide di membrana, la sfingomielina, lo 
rende abile nel modulare la fluidità del doppio strato lipidico di membrana, determinante per 
l’innesco di molti processi cellulari. Recenti studi, riportano una evidente relazione tra alti livelli di 
espressione dell’A-SMase e numerose patologie caratterizzate da una forte componente 
infiammatoria (Schissel et al., 1998; Devlin et al., 2008; Garcia-Ruiz et al., 2015). I nostri risultati 
rivelano che l’espressione dell’A-SMase aumenta significativamente in seguito a danno muscolare 
acuto, dimostrando il suo coinvolgimento nell’infiammazione del muscolo scheletrico. Inoltre, 
abbiamo anche dimostrato l’importanza dell’enzima nella regolazione del processo di rigenerazione 
muscolare conseguente al danno acuto. In seguito a danno muscolare, abbiamo scoperto che 
l’assenza di A-SMase causa un incremento sia del numero delle cellule satelliti, essenziali per la 
rigenerazione muscolare, che del numero delle miofibre rigeneranti nella sede di lesione. Inoltre, 
MyoD e Myogenin, due importanti fattori trascrizionali, responsabili di una corretta rigenerazione 
muscolare, mostrano livelli di espressione più alti in assenza di A-SMase, indicando un processo di 
rigenerazione accelerato. Anche IGF-1, un fattore di crescita cruciale nel promuovere la 
rigenerazione muscolare, mostra livelli di espressione più alti in assenza dell’A-SMase, 
coerentemente con la nostra evidenza precedente in cui abbiamo riportato che in assenza 
dell’enzima il processo di rigenerazione è accelerato. Molto importante, i nostri risultati forniscono 
la prima evidenza sperimentale di un nuovo ruolo dell’A-SMase nella regolazione del fenotipo dei 
macrofagi durante la rigenerazione muscolare. Mediante esperimenti in vitro, infatti, abbiamo 
dimostrato la capacità dell’enzima di regolare la polarizzazione dei macrofagi verso un fenotipo 
pro-infiammatorio (M1): l’assenza di A-SMase comporta una riduzione significativa 
dell’espressione di marcatori specifici per il fenotipo M1. Inoltre, investigando il ruolo dell’A-
SMase nei muscoli del topo mdx, modello animale per la Distrofia muscolare di Duchenne (DMD), 
abbiamo individuato un incremento significativo sia dell’espressione che dell’attività dell’idrolasi 
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dimostrando il coinvolgimento dell’enzima nella patogenesi della DMD, in particolar modo 
nell’insorgenza dell’infiammazione. Diversi studi riportano il ruolo predominante 
dell’infiammazione nella patogenesi della DMD (Villalta et al., 2009; Radley et al., 2008). I nostri 
dati dimostrano che l’aumento dei livelli di A-SMase osservato nel topo mdx coincide con 
l’incremento dello stato infiammatorio presente nel muscolo degli stessi. Questa evidenza è stata 
corroborata dall’utilizzo del farmaco anti-infiammatorio Naproxcinod in grado di ridurre 
l’infiammazione muscolare nel topo distrofico e nel contempo diminuire significativamente 
l’espressione e l’attività dell’A-SMase.  
In conclusione, i nostri risultati aprono a nuove prospettive nell’identificazione dell’A-SMase come 
possibile bersaglio farmacologico durante lo sviluppo e la regolazione del processo infiammatorio e 
di rigenerazione muscolare contemplando la possibilità che la modulazione dei livelli di espressione 
dell’enzima possa apportare benefici terapeutici non solo nella distrofia di Duchenne ma anche in 
altre malattie da deperimento muscolare.  
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INTRODUCTION  
 
Chapter 1: Skeletal muscle development 
Skeletal muscle is a complex and heterogeneous tissue fundamental for several functions in the 
organism. Myogenesis is the process responsible for the muscle generation and it can be divided in 
several distinct phases (Tajbakhsh et al., 1997). Skeletal muscle is originated during embryonic 
myogenesis from somites, which are transitory structures fundamental in organizing the segmental 
plan of vertebrate embryos (Aulehla; Pourquiè, 2010). The somites are detached from one another 
and subsequently due to local molecular signals, they differentiate into three portions: sclerotome, 
myotome and dermatome. During the development of skeletal muscle the myotome cells separate, 
migrate in the appropriate areas and generate myoblasts. Some progenitor cells do not differentiate 
in order to give rise to the myogenic precursors, Satellite Cells (SCs), located in a niche on the 
surface of the muscle fibre, beneath the basal lamina of the muscle cells. Skeletal muscle 
development during embryonic, fetal and neonatal periods requires successive waves of muscle 
stem cell activation, proliferation and fusion that involve different types of myoblasts (Zecchini et 
al., 2018).  
A hierarchy of transcription factors regulates the progression of myogenesis. The basic helix-loop-
helix factors such as Myogenic Differentiation (MyoD), Myogenic factor 5 (Myf5), Myogenin, and 
MRF4 (Myf6) are expressed in the skeletal muscle lineage and are considered as myogenic 
regulatory factors (MRFs) (Weintraub et al., 1991; Rudnicki and Jaenisch, 1995). Myf5 and MyoD 
act upstream of Myogenin and MRF4 to specify myoblasts for terminal differentiation. Myogenin 
and MRF4 are involved in the differentiation process and trigger the expression of myotube-specific 
genes (Bentzinger et al., 2012). The next degree of genetic hierarchy regulating myogenic process is 
occupied by the paired-homeobox transcription factors, Pax3 and Pax7. All vertebrates have at least 
one of these genes. Pax3 positive cells are founder cells forming a template of initial fibers in the 
limb to which Pax7 positive cells then contribute by forming secondary fibers and establishing the 
satellite cell pool (Maqbool and Jagla, 2007).  
SCs are responsible for generating myoblasts in postnatal skeletal muscle (Katz, 1961; Mauro 
1961); indeed, they initially provide myoblasts for muscle growth, before becoming mitotically 
quiescent as the muscle matures. In adults, SCs can be recruited to supply myoblasts for muscle 
fiber homeostasis, or for the myofiber repair (Zammit, 2008). 
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Moreover, SCs are able to maintain their own population by self-renewal, satisfying the criteria of a 
stem cell (Collins et al., 2005).  
  
  
 
 
 
Figure 1: Genetic hierarchy of transcription factors regulating myogenic progression (Bentzinger et al., 2012) 
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1.1 Structure and function  
Skeletal muscle is one of the most dynamic and plastic tissues of the body. Muscle mass depends on 
the balance between protein synthesis and degradation and both processes are sensitive to factors 
such as nutritional status, hormonal balance, physical activity/exercise, and injury or disease, among 
others (Frontera and Ochala, 2015). Skeletal muscle is a key component of several bodily functions 
such as locomotion, contraction, maintenance of posture, respiration, constriction of organs and 
vessels and production of body heat. Long cylindrical muscle fiber, also called myofiber, is the 
functional unit of skeletal muscle, which is able to generate force by contraction.  
The skeletal muscle architecture consists of three different connective tissue layers: epimysium, 
perimysium and endomysium. The epimysium is the connective tissue, which surrounds the entire 
skeletal muscle; from epimysium originates the perimysium, which surrounds groups of muscle 
fibers and the last but not least, the endomysium a reticular connective tissue surrounding each 
muscle fibre. Each myofiber is packed with myofibrils composed of thousands of sarcomeres that 
contain the actin and myosin filaments that interact to produce the force (Relaix and Zammit, 2012) 
(Fig.2).  
Muscle fibers are syncytial and multinucleated cells that often containing hundreds of myonuclei 
within a continuous cytoplasm.  
 
 
 
Figure 2: Representation of muscle fiber structure 
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1.2 Skeletal muscle regeneration 
Skeletal muscle has a great capacity to regenerate new muscle fibers after severe damage by injury 
or by degenerative diseases such as muscular dystrophy (Tedesco et al., 2010). The regeneration 
process is very efficient. Indeed, the muscular function is restored even when a muscle is removed 
and replaced back in situ (Studitsky, 1964).  
This regenerative capacity relies on muscle progenitor cells SCs that have stem cell properties and 
are responsible for generating myoblast in both postnatal growth of skeletal muscle and possible 
repair processes (Mitchell et al., 2010). Muscle regeneration is a highly coordinated process 
involving a variety of cell types and signaling molecules that work systematically to repair the 
damaged myofibers (Brack et al., 2012). Muscle regeneration recapitulates many stages of muscle 
development because the molecular program that underlines prenatal development is reactivated for 
tissue reconstruction; however, during adult regeneration after injury, extrinsic factors are different 
from those during embryonic development (Nie et al., 2016).  
Skeletal muscle regeneration consists of five and time-dependent phases: degeneration (necrosis), 
inflammation, regeneration, remodelling, and maturation/functional repair (Fig.3) (Musarò, 2014). 
 
 
 
Figure 3: Schematic model of the muscle regeneration process (Advances in Biology, Vol.2014, Review, Musarò) 
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The degeneration phase is characterized by necrosis of myofibers and involves the influx of 
calcium ions, the loss of the plasmalemma, myonuclear, contractile material and cellular organelles 
dissolution. Necrotic fibers show an altered internal architecture with the presence of internal 
nuclei, which may reflects the invasion by macrophages. Necrotic cell death stimulates a host 
inflammatory response.  
Inflammation of injured skeletal muscle plays a critical role in muscle homeostasis and regeneration 
and it is responsible for the recruitment of specific myeloid cell populations within the injured area. 
The immune system plays a crucial role during skeletal muscle regeneration: neutrophils are the 
first inflammatory myeloid cells recruited at the site of muscle injury by interacting with adhesion 
molecules of vascular endothelial cells. The phagocytic activity of neutrophils is responsible for the 
release of high concentrations of free radicals and the secretion of pro-inflammatory cytokines that 
stimulate the homing of other inflammatory cell populations such as monocyte and macrophages 
(Tidball et al., 2005). Macrophages are a heterogeneous population of innate myeloid cells and are 
considered the predominant inflammatory cell types. They rapidly increase within 24 hours after 
injury and are detectable at perimysium and epimysium. The role of macrophages is very important 
because they are able to remove tissue debris and activate stem cell populations (Pimorady-Esfahani 
et al., 1997).  
 
 
 
 
 
Figure 4: Schematic diagram of time-dependent cellular response following muscle injury (Advances in Biology, 
Vol.2014, Review, Musarò) 
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The central role of macrophages in regulating the inflammatory process depends on their capacity to 
polarize in different phenotypes that can orchestrate or counteract inflammation in response to 
trauma. Interestingly, different inflammatory processes mediated by macrophages play a significant 
role in the pathogenesis of several muscular dystrophies such as Duchenne Muscular Dystrophy.  
The first steps of the inflammatory response are associated with the “classically activated” (M1) 
macrophages, which produce pro-inflammatory cytokines. In contrast, the resolution of 
inflammation is associated with the “alternatively activated” anti-inflammatory (M2) macrophages 
(Xuan et al., 2014). Macrophages can undergo dynamic transitions between M1 and M2 states 
called “polarization skewing” and sequentially, change their functional phenotype in response to 
changes in microenvironmental influences (Stout et al., 2005). M1 macrophages are activated by T-
helper (Th) 1 cytokines interferon-gamma (IFNγ), Tumor Necrosis Factor-alpha (TNF-α), 
Lipopolysaccharide (LPS), Interleukin-6 (IL-6) and IL-1. The M2 population can be divided into 
three possible subtypes known as M2a, M2b and M2c macrophages. Their activation changes 
according to the type of subpopulation: M2a cells are induced by exposure to IL-4 and IL-13, M2b 
types are activated by combined exposure to immune complexes and toll-like receptors (TLR) or 
IL-1R agonists and M2c classes are induced via IL-10. Each class has a specific function. M2a and 
M2b macrophages exert immunoregulatory functions whereas M2c types are involved in the 
suppression of immune responses and tissue remodelling (Mantovani et al., 2004). The transition 
from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype is necessary for proper and 
efficient muscle growth and regeneration (Lawrence and Natoli, 2011). Nevertheless, until now, the 
signaling pathway responsible for the polarization skewing is not entirely clear. 
 
 
Table 1: Characteristics of macrophage subtypes (Advances in Biology, Vol.2014, Review, Musarò) 
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M2 macrophages play an important role in deactivating M1 macrophages, in fact, in terms of a 
functional regeneration, M2 appear soon after M1. Sometimes, under specific pathologic conditions 
such as muscular dystrophy disease, it is possible that the M1 macrophages are accompanied by the 
contemporaneous invasion of M2a influx. This simultaneous recruitment of macrophage 
populations is responsible for the reduction of muscle damage caused by M1 subset (Tidball and 
Villalta, 2010; Villalta et al., 2009). The inflammatory response is a coordinated process finely 
regulated and able to promote an efficient regenerative process. It is well known that the perturbed 
spatial distribution of inflammatory cells can alters identity of the inflammatory infiltrate by 
disrupting temporal sequence that leads to a persistent inflammatory phase (Douglas et al., 2002).  
The muscle regeneration phase is guaranteed by the role of SCs. Normally, they reside between the 
basal lamina and sarcolemma of myofibers. Upon physiological stimuli such as growth, exercise or 
pathological states represented by muscle injury or degenerative diseases they are activated (Mauro, 
1961). When activated, SCs come out from their quiescence state and start repairing damaged 
muscle fiber by fusing with the existing myofibers or to each other in order to form new myofibers 
(Gayraud et al., 2009). However, not all the SCs differentiate, in fact, a little minority reenters into 
the quiescence state to preserve the stem cell pool (Zammit et al., 2004). During the different stages 
of skeletal muscle differentiation, SCs express different markers. The quiescent SCs are recognized 
for the presence of Pax3, CD34, Integrin α7 and other specific markers showed in the picture below 
(Fig.5).  
 
 
Figure 5: The molecular markers of satellite cells during the different stages of skeletal muscle regeneration 
(Advances in Biology, Vol.2014, Review, Musarò) 
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The main markers that characterize the proliferating SCs state are Pax7, MyoD, Ki67 and Myf5. 
Once activate SCs can down-regulate MyoD in order to self-renew and to preserve the pool of 
quiescent Pax7+ positive cells. Otherwise, SCs can keep the MyoD expression down-regulating 
Pax7 and activating Myogenin expression by committing to differentiation of SCs (Boldrin et al., 
2010; Relaix et al., 2012). 
 
 
Figure 6: Schematic representation of satellite cells activation after injury (Yablonka–Reuveni et al., 2008) 
 
In this context, the sequential presence of M1 and then M2 macrophages accompany the entire 
process of muscle regeneration. In fact, M1 subset is able to stimulate the SCs proliferation whereas 
M2 macrophages can promote their differentiation (Arnold et al., 2007; Saclier et al., 2013).  
The remodeling phase represents the fourth stage of muscle regenerative process in which the 
extracellular matrix plays an important role in the production of different types of Collagens, 
Elastin, Laminin, Fibronectin and Proteoglycans (Mutsaers et al., 1997). All these components are 
necessary to stabilize the tissue, to lead the formation of neuromuscular junctions and to serve as 
scaffold for the new fibers (Lluri et al., 2006).  
The repair of injured myofibers is the last phase of the process; it is completed when the myofibers 
recover their functional activity and the regenerated muscles are re-vascularized and re-innervated 
(Pelosi et al., 2007).  
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Chapter 2: Muscular Dystrophies 
Muscular dystrophies are a genetically, biochemically and clinically heterogeneous group of 
inherited disorders with clinical and dystrophic pathological features on muscle biopsy (Emery, 
2002). Progressive muscle weakness that interests limb, axial and facial muscles is the prominent 
feature of the muscular dystrophies profile. Moreover, other muscles such as respiratory, 
swallowing and cardiac smooth muscles can be affected. In specific forms of disorder, there is also 
the involvement of other different organs or tissues such as the brain, eyes, skin or inner ear. The 
severity and the age of onset of these disorders change largely with the different form of the variant. 
As a rule, congenital muscular dystrophies have clinical signs at birth or in the first few months of 
life. Many other forms manifest their symptoms in early or late childhood or adolescence unlike 
other muscular dystrophies that not manifest clinical signs until adulthood. The distribution of the 
skeletal muscle weakness is quite important because it can help to distinguish between different 
forms of muscular dystrophy and in several cases allows to the disorder to be suspected rapidly 
(Emery, 2002; Guglieri et al., 2008; Quinlivan et al., 2010). Muscle weaknesses can be associated 
with the presence of either muscle atrophy or hypertrophy, or both. Joint contractures and scoliosis 
are other symptoms that arise in specific variants. The progression of each form depends on the 
different dystrophy variants. In patients affected by congenital muscular dystrophy, ambulation is 
never achieved, whereas in the childhood onset forms the ambulation is achieved but will be lost 
during the rapidly progression of variant; generally, it occurs by the early or middle teenage years. 
In most cases of muscular dystrophies, the ambulation can be maintained and the wheelchair 
assistance is needed only later in life. Moreover, respiratory impairment is frequent but its severity 
is not always related to the degree of motor impairment. Cardiac involvement is also common and 
variable in many muscular dystrophies but is not the main feature (Mercuri and Muntoni, 2013). 
The mechanisms underlying the muscular dystrophies have been thoroughly studied in order to give 
rise of specific criteria about their classification. Indeed, the classification cannot be based only on 
the previous suppositions indicating that every clinical phenotype is associated to a distinct genetic 
defect. In fact, individual phenotypes are often associated with mutations in different proteins that 
share similar cellular functions (Mercuri and Muntoni, 2012; Guglieri et al., 2008; Muntoni and 
Voit, 2008).  
Progression of the disease is controlled by the severity of the individual mutation affecting each 
gene. The main class of proteins involved in the muscular dystrophy context including external 
membrane and extracellular matrix proteins, enzyme or protein with putative enzymatic function, 
sarcolemma-associated proteins, sarcomeric proteins and nuclear membrane proteins.  
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Abnormalities in the external and extracellular proteins such as Laminin and Collagen VI are 
responsible for congenital onset of weakness, which suggest an important role of these proteins in 
prenatal skeletal muscle development and function (Mercuri and Muntoni, 2012).  
The enzyme or protein with putative enzymatic function can be divided in the proteins involved in 
the glycosylation of α-dystroglycan and those that are not involved in this process. The 
glycosylation of α-dystroglycan is very important; in fact, a defected process is the major cause of 
the congenital and Limb-Girdle muscular dystrophies (Muntoni et al., 2010; Muntoni et al., 2002). 
The proteins that are not involved in the glycosylation of α-dystroglycan are represented mainly by 
Calpain3, which belongs to a family of calcium-activated neutral proteases, and interacts with 
several proteins important for muscle functions. This protein is involved in the Limb-Girdle A, 
characterized by a dysfunction in calcium-calmodulin protein kinase II signaling (Kramerova et al., 
2012).  
Proteins belong to the sarcolemma are responsible for the most common forms of muscular 
dystrophies in childhood, the Duchenne (DMD) and Becker (BMD). The main sub-complex, called 
dystrophin-associated-glycoprotein (DGC) is fundamental for the stabilisation of the muscle fibre 
against the mechanical stress of muscle contraction by representing an important connection 
between the cytoskeleton and the extracellular matrix (Khairallah et al., 2007). With the 
destabilisation of the DGC, muscle fibers become more sensitive to stretch-induced damage and 
necrosis leads to weakness and muscle regeneration.  
 
 
 
Figure 7: Sarcolemma and proteins involved in muscular dystrophies (The Lancet; Mercuri and Muntano, 
2013).  
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Defects in sarcomeric proteins are responsible for dystrophic phenotypes with mainly distal 
distribution of weakness. Mutations in the proteins located in the outer or in the inner-nuclear 
membrane such as Lamin A/C, Emerin, Nesprin 1/2 and LUMA result in disorders with progressive 
muscular dystrophy phenotype, originally described by Emery and Dreifuss with humeroperoneal 
weakness and coexistent cardiac involvement (Emery and Dreifuss, 1966).  
For the diagnosis of specific form of muscular dystrophy the combination of clinical signs and an 
analysis of the mode of inheritance are fundamental although the overlaps between genetically 
distinct variants makes identification more difficult. Often, patients affected by muscular dystrophy 
showed up to ten times higher than normal values of serum creatinine kinase, a chemical waste 
molecule generated from muscle metabolism. Moreover, electromyography can help in the 
diagnosis of several dystrophies but it has low value in the identification of a specific disorder in 
patients with elevated serum creatinine kinase. Other important diagnostic methods are muscle 
biopsy and Western blotting analysis. The former allows assessing the morphology excluding 
disorders with overlapping features such as myofibrillar myopathies. The latter, uses antibodies to 
find the level and localisation of different muscle proteins in order to calculate their abundance and 
identify the primary protein defect to direct genetic testing (Mercuri and Muntoni, 2013).  
The identification of genetic defects is the gold-standard diagnostic method because not all 
dystrophies are caused by protein deficiency. In many diagnoses of neuromuscular dystrophies  
muscle imaging can be used in order to identify disease-specific patterns of muscle involvement 
(Mercuri et al., 2007).  
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2.1 Duchenne Muscular Dystrophy  
Duchenne Muscular Dystrophy (DMD) is the most severe and diffuse type of dystrophies group 
with a high incidence (1out of 3.500 boys) affecting mainly skeletal muscle. DMD is a fatal X-
linked disease caused by a wide range of mutations in the dystrophin gene, the largest gene inside 
the human genome (Govoni et al., 2013). At present, more than 4.700 mutations on dystrophin gene 
have been detected: deletions (65.8%) and duplications (13.6%) are responsible for the majority of 
gene mutations. Point mutations such as micro-insertions, micro-deletions, non-sense, missense and 
splicing mutations represent the 20.6% only (Magri et al., 2011).  
In muscles of patients affected by DMD the dystrophin mutations accounting for premature stop 
codons or change the reading frame of the gene resulting in the complete loss of the protein. 
Generally, the onset of DMD is before the third year of age. Typically, the disease implies 
ambulation loss between 10 and 14 years of age with the die of patient around 20- 30 years of age 
caused by hypoxemia, hypercapnia and hypoventilation associated with diaphragm wasting, which 
is the most affected muscle in DMD and responsible for respiratory failure (Davies et al., 1988; 
Fayssoil et al., 2010). The DMD disorder also involves cardiac and smooth muscles. More than 
90% of DMD patients show cardiomyopathy, which is responsible for a progressive impairment of 
the ejection fraction leading to arrhythmias and heart failure (Mosqueira et al., 2013; Jefferies et al., 
2005).  
 
 
                       Figure 8: Timeline Duchenne Muscular Dystrophy patients.  
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In healthy muscle, dystrophin is located at the subsarcolemma and interacts with many membrane 
proteins forming the dystrophin glycoprotein complex (DGC), which is responsible for the 
stabilization of muscle cell membrane during cycles of contraction and relaxation. The DGC 
complex is also involved in the regulation of mechano-sensitive calcium channels, by influencing 
calcium homeostasis and signaling (Willmann et al., 2008). In the DGC structure, dystrophin 
represents the main cytoskeletal scaffolding protein and it is able to recruit crucial structural and 
signaling factors to the muscle membrane by creating a highly organized network.  
The DAG complex contains many tissue specific transmembrane proteins such as β-dystroglycan, 
α, β-, γ-, δ-,ε-,and ζ-sarcoglycans, sarcospan and caveolin 3, extracellular proteins which are α-
dystroglycan and Laminin, and also several sarcoplasmic proteins such as α- and β-dystrobrevins, 
α1, β1-,β2-,γ1-, γ2 syntrophins and neuronal nitric oxide synthase (nNos).  
The proteins in the DGC complex are tightly connected to each other, therefore, every single 
modification in one of these proteins, also affects the others and hence it is responsible for different 
muscular defects. In DMD disorder, the disintegration of the dystrophin associated to DGC 
structure is responsible for the relocation of the nNOS in the sarcolemma by generating low NO 
production. The reduction of NO reduces muscle bulk and force generation, causing increased 
fatigability (De Palma and Clementi, 2012).  
Therefore, the absence of dystrophin protein makes the muscle fibres more sensitive to mechanical 
contraction than the healthy fibres (Lynch et al., 2010). In fact, in response to contractile stress, they 
undergo continued cycles of necrosis and regeneration during which the multipotent myogenic 
precursor pool, into skeletal muscle fibres, the satellite cells, lead to muscle regeneration process 
(Le Grand and Rudnicki, 2007; Biressi and Rando, 2010). The repeated cycles of necrosis and 
regeneration exhaust the skeletal muscle regenerative potential resulting in an inefficient process 
characterised by gradual substitution of muscle with fat and connective tissue. These are the reasons 
why the loss of dystrophin leads to chronic and local inflammation, progressive muscle wasting and 
weakness, exhaustion of satellite cell pool and an impaired muscle regenerative process. 
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2.2 Mouse models for DMD 
The physiopathology of DMD has been widely studied and the most of knowledge on the molecular 
mechanisms underlying the disease derived from studies in different mammalian models for DMD. 
The first dystrophin-deficient mutant was described in 1984 in a colony of C57BL/10 mice 
(C57BL/10ScSnJ) (Bulfield et al., 1984) referred as the “mdx-mouse”. This mouse, also called 
C57BL/10ScSn-Dmdmdx/J, is widely used in basic and translational research; it carries a point 
mutation in exon 23 of the mouse dystrophin gene introducing a premature stop codon, which leads 
to the absence of full-length dystrophin. This type of mutation is responsible for approximately one 
third of the mutations found in DMD patients (Willmann et al., 2008).  
The mdx mice have a shorter life compared to wild type controls. A prominent degeneration and 
regeneration of muscle fibers is observed in the young age between 2 and 4 weeks by resulting in an 
increase in the number of newly differentiating myofibers characterized by centralized nuclei and 
an increased heterogeneity in myofiber size (McGeachie et al., 1993). At the same early age, mdx 
muscles show necrosis that decrease after 60 days (Bulfield G. et al., 1984). Among mdx muscles, 
the diaphragm is the only one with a marked fibrosis unlike to the other muscles which show less 
fibrosis also compared to DMD patients. The mdx mice have an absolute muscle force unaffected 
but a reduction in the relative force normalized to body weight. At 16 months of age mdx mice 
show an evident worsening of respiratory capacity in parallel to the increased histological damage 
of respiratory muscle (Gayraud et al., 2007). Another pathological feature of mdx muscles is an 
abnormal cardiac function characterized by myocardial fibrosis, necrosis and inflammation. 
Therefore, this model is considered a valid preclinical model to better understand cardio-protective 
pharmacological approaches (Quinlan et al., 2004). Moreover, since the subsarcolemma 
compartment and sarcoplasmic reticulum of mdx muscles show increased levels of calcium, it 
represents a valid model to investigate the calcium homeostasis and its possible alterations (De 
Backer et al., 2002). 
 
- mdx variants  
Other models for DMD are the mdx variants defined as mdx2Cv, mdx3Cv, mdx4Cv, and mdx5Cv that not 
differ from the original mdx mutant; in fact, the mice show muscle dystrophic condition and 
elevated serum creatine kinase levels as well as the first mdx generated. The muscle 
immunohistochemistry revealed degeneration and regeneration in muscle fibers, centrally nucleated 
fibers, cellular infiltration and necrosis. The diaphragm shows fibrosis as well as the diaphragm of 
the original mdx mice. The muscle fiber size of the mdx variants is larger than in mdx mice and at 4 
weeks of age the mdx2Cv and mdx3Cv models show an abnormal slow contraction/relaxation of 
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muscles and some fibrosis in the heart. The mdx3Cv variant has a reduced neonatal survival 
(Chapman et al., 1989; Cox et al., 1993).  
The mdx variant mdx52 was created in order to get a mouse model with large deletions in the 
dystrophin gene like those observed in two thirds of human patients. To this end, the exon 52 was 
disrupted on a C57BL/6J background. Tibialis Anterior and Extensor Digitorum-longus muscles of 
mdx52 are 1.5 times larger than wild type muscles at 4 months of age. In this age, variation of fiber 
size, necrotic sites and central-nucleated fibers predominate. Until 18 months of age in these mice, 
there is no evidence of skeletal muscle weakness. Fibrosis only affects diaphragm, Soleus and 
Extensor Digitorum-longus muscles. Heart and brain do not show pathological changes (Araki et 
al., 1997). 
 
- mdx double mutants 
In order to better understand the mechanism underlying the DMD pathology, double mutant mice 
models have been created. They have different and additional knockout genes and are termed as 
mdx; utr-/-, mdx; MyoD-/-, mdx; adbn-/-, mdx; α-7integrin-/-, mdx: PV-/-. Each double mutant 
represents a specific model able to resemble specific features of DMD pathology. For example, mdx 
mice knockout for utrophin, a dystrophin related proteins, (mdx; utr-/-) loses both utrophin and 
dystrophin by showing a dystrophic phenotype that remains severe without any improvements. As 
these mice show interstitial fibrosis of skeletal muscle, this model is useful to assess the efficacy of 
anti-fibrotic treatment.  
The muscle regeneration is an ineffective process in DMD patients. This is the reason that leads to 
the creation of a mouse model with a reduced capacity to regenerate given by the mdx; MyoD-/-.  
MyoD is involved in the muscle differentiation and mutants for this gene show evident muscle 
dystrophy phenotype with cardiomyopathy. Therefore, this model has been proposed as a model of 
DMD associated to cardiomyopathy.  
Moreover, the mdx mice knockout for α-dystrobrevin, a protein of DGC complex, has been created 
in order to investigate the role of this protein in signaling and in muscle stability. These animals 
display a more severe dystrophic phenotype than mdx but not as severe as the mdx knockout for 
utrophin.  
The main integrin expressed in skeletal muscle is α7β1. Data from literature suggest its capacity to 
act in synergy with DGC in order to connect the extracellular matrix to the cytoskeleton. To test this 
evidence a double mutant model for α7-integrin and dystrophin has been created. These mice show 
an aggravated phenotype suggesting the importance of α7-integrin levels in different clinical 
severity of dystrophin deficiency in human and mouse (Guo et al., 2006). 
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Since mdx mice show a relatively mild pathology when compared to the DMD patients, has been 
investigate whether this difference might be due to the high levels of the calcium-buffer 
parvalbumin (PV) in the skeletal muscle of rodents. So mdx mice were crossed with PV knockout 
mice (PV-/-). The mdx; PV-/- are similar to mdx mice but they show a more number of central-
nucleated fibers compared to mdx. Furthermore, muscles from 90 day old of double mutants are 
weaker in comparison to mdx in vitro and in vivo. Currently, although the PV levels are high, they 
are not able to explain the difference to DMD phenotypes (Willmann et al., 2008).  
 
 
2.3 Pharmacological approaches to muscular dystrophy 
 
Corticosteroids treatment 
At the moment, despite much is known about the underlying molecular mechanism of muscular 
dystrophies, they are still considered the most difficult diseases to treat (Cossu and Sampaolesi, 
2004). The current pharmacological treatments are not able to cure the different forms of muscular 
dystrophy but can delay disease progression and relieve symptom by improving the quality of life in 
order to extend the lifespan. The musculoskeletal system of patients affect by DMD undergoes the 
lack of structural protein dystrophin that cause a chronic influx of calcium in muscle fibers leading 
to cell death and inflammatory state (Hamid and Clemens, 2012). For these reasons corticosteroids 
treatment has been the first pharmacological therapy suggested in the 1974, in order to prevent 
muscle necrosis by stabilizing the muscle membrane and counteract the inflammation (Drachman et 
al., 1974). Currently, corticosteroids administration represents the gold standard therapy for DMD 
and other forms of muscular dystrophy. Corticosteroids are tested in different trials in order to 
define the optimal dose, frequency and age of initiation (Griggs et al., 1993; Escolar et al., 2011). 
Until now, they are considered the only pharmacological treatment able to give benefits by delaying 
the progression of the disease and prolonging at least two years the time before the loss of 
ambulation (Hamid and Clemens, 2012; Goemans et al., 2014). Unfortunately, corticosteroids are 
associated with severe side effects. DMD patients treated with steroids are also at risk of loss of 
bone density, hypertension, metabolic disorder, long bone fractures, and vertebral compression 
fractures. Sometimes, steroid-induced behavioural problems forced a limited long-administration 
(Mendell et al., 2012). The corticosteroids mainly used for DMD are Prednisone/Prednisolone and 
Deflazacort, an alternative, sodium-sparing glucocorticoid. The efficacy of these drugs has been 
established by performing a randomized, double blind controlled trial in boys with DMD. After 6 
months of Prednisone treatment, boys showed an improvement in the muscle strength and function, 
INTRODUCTION 
23 
 
as well as the time needed to rise from supine to standing, to walk 9m and to climb four stairs (p < 
0.001 for all comparisons) when compared to boys treated with placebo. Moreover, from 6 months 
patients had an increase in urinary creatinine excretion, which suggested an increase in total muscle 
mass (Mendell et al., 1989). Similar results were then documented using Deflazacort, which is able 
to prolong ambulation (p <0.005) (Biggar et al., 2006). The mdx mouse model has been used to 
investigate the mechanism of action of corticosteroids.  
Several studies indicate that Prednisone and Prednisolone have an anti-inflammatory effect, 
increase the force of skeletal muscle but have no functions on muscle fibers regeneration (Wehling-
Henricks et al., 2004). In contrast, Deflazacort reduces the skeletal muscle pathology by acting on 
muscle regeneration and differentiation (Anderson et al., 2000). Furthermore, other studies 
demonstrated that the long-term corticosteroids treatment in mdx mice is responsible for the 
increase of fibrosis on cardiac muscle suggesting that this mouse model could not be an appropriate 
positive control in long-term pharmacological studies (Sali et al., 2012).  
 
 
Histone deacetylase inhibitors as an alternative approach to corticosteroids treatment  
Data from literature demonstrated that in dystrophic condition there is a high activity of histone 
deacetylases (HDAC), a class of enzymes that modulates the gene expression. 
HDACs allow the histones to wrap DNA more tightly in condenses DNA structure preventing 
genetic transcription (Colussi et al., 2008; Illi et al., 2009). So, another pharmacological strategy is 
based on the use of histone deacetylase inhibitors (HDACi) in order to modify chromatin structure 
and allows the genetic transcription. Givinostat, originally ITF2357, is a histone deacetylase 
inhibitor with anti-inflammatory, anti-angiogenic and anti-neoplastic activities. In mdx mice, 
HDACi are able to slow disease progression, reduce fibrotic tissue, fatty infiltration and increase 
cross-sectional area of myofibers (Colussi et al., 2008; Consalvi et al., 2013). 
 
Gene therapy 
Duchenne and Becker muscular dystrophies are characterized by the lack or alteration of dystrophin 
protein. Gene replacement approach arises with the purpose of counteracting the dystrophin lack 
and replacing the defective dmd gene by using delivery vehicles such as adeno-associated viruses 
(AAV) and lentivirus based vectors. Gene replacement technologies should be applicable regardless 
the patients genetic mutation. Further, the use of AAV is advantageous given its capacity to stably 
persist in muscle cells for years without arise of pathogenicity (Wright et al., 2008).  
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Since dystrophin gene size is very big, this represents a limitation of AAV vectors, as they are not 
able to delivery large genes. An attempt to overcome this limit is to realize micro but functional 
dystrophin gene to insert into the vector (Seto et al., 2014). Another alternative is given by trans 
splicing, a method able to reconstitute the whole gene. This reconstitution consists in co-delivery of 
two or more AAVs with the gene of interest split between them, in order to reform the entire gene 
and deliver it into muscle cells (Li et al., 2008). Albeit this strategy could seem an extraordinary 
finding, it has a big limit given by the host immune response against both the viral vector and the 
delivered protein. For this reason, different AAV serotypes have been tested in order to reduce the 
host immune response. AAV2/8, chimeric vectors, has been tested on mdx mice and has been 
demonstrated its ability to restore dystrophin expression in heart and skeletal muscle without 
immune response (Van Westering et al., 2015).  
 
 
Exon Skipping and Antisense Oligonucleotides  
In DMD and BDM, the dystrophin gene undergoes to single or multiple exons deletion that cause a 
shift of the reading frame. The result is a non-functional dystrophin protein (Kole et al., 2015). 
From these data the idea to develop the antisense-mediated exon skipping strategy arises in order to 
increase dystrophin expression in dystrophic muscle by restoring the reading frame (Douglas et al., 
2013). The antisense oligonucleotides (AONs) do not contain more than 20-30 nucleotides. They 
are able to bind specific pre-mRNA sequences (mutated exons) in order to allow their skipping at 
the moment in which the gene is translated by restoring the reading frame (Harding et al., 2007).  
 
 
 
Figure 9: Example of anti-sense oligonucleotides activity (Kole and Krieg, 2015; Advanced Drug Delivery 
Reviews). 
 
Many AONs were developed and tested both in vivo and in vitro (Benedetti et al., 2013). The most 
AONs studied have been morpholino phosphorodiamidate oligomers (PMOs) and phosphorothioate 
oligonucleotides (PS). The AAV vectors have been used as a vehicle to deliver AONs by resulting 
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in a restored dystrophin expression and in an improvement in the pathology of dystrophic muscles 
mice (Goyenvalle et al., 2004; Goyenvalle et al., 2012). As the dystrophin levels restoration decline 
in the time and the AAV are lost, repeated injections are needed. Currently, AAV mediated exon 
skipping is in preclinical stages to treat DMD patients (Le Hir et al., 2013). Unfortunately, until 
now there are no clinical benefits from antisense therapy in DMD because of low tissue uptake and 
recovery of dystrophin expression (Tedesco et al., 2012). Therefore, modifications in AONs 
chemistry are necessary to ameliorate cellular uptake and reduce the clearance by the organs such as 
liver and kidney (Miura et al., 2006). Interestingly, tricycle-DNA (tcDNA), a new class of AONs 
and an analogue of DNA, has a good uptake from many tissues in two mouse models of DMD. 
After systemic administration of tcDNA, skeletal muscles and heart showed high dystrophin rescue 
with an ameliorated phenotype of dystrophic mouse. These new AONs represent a precious tool not 
only for DMD pathology but also for other diseases in which can be possible apply antisense 
oligonucleotides by systemic treatment (Miura et al., 2006).  
 
 
Cell therapy 
As the loss or alteration of dystrophin is the main cause of the DMD pathology, new 
pharmacological approaches have been designed in order to replace dystrophin by transplantation of 
cells carrier a functional dystrophin gene. This strategy called cell therapy aims to restore the lost 
muscle mass and arrest the disease progression (Seto et al., 2014). Satellite cells play an essential 
role in muscle regeneration after injury. In DMD muscles, continuous cycles of damage and 
regeneration caused a reduction in the capacity of satellite cells to self-renew and restock muscle 
damaged. The first cell sources for DMD cell therapy have been myoblasts harvested from healthy 
donors and then transplanted in DMD patients by local intramuscular injection in order to 
reintroduce the dystrophin expression. This approach was not successful owing to the low 
migration, survivability and immune rejection of transplanted cells (Fan et al., 1996; Skuk et al., 
2006; Skuk et al., 2011).  
Satellite cells are not only the cell sources of myofibers; in fact, other stem cell types able to 
differentiate into myofibers such as, the bone marrow derived stem cells, mesenchymal cells and 
mesoangioblasts can be used for cell therapy. Mesoangioblast, the myogenic vessel-associated 
stem/progenitor cells, influence muscle regeneration thanks to their high migration ability to injured 
site (Minasi et al., 2002; Sampaolesi et al., 2003). Intra-arterial delivery of mesoangioblasts leads to 
a significant amelioration of muscle structure and function by representing a promising cell therapy 
for muscular dystrophy (Sampaolesi et al., 2003).  
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Recently, data from literature emphasized the therapeutic use of pluripotent stem cells such as 
embryonic stem cells (ESC) and induced pluripotent stem cells (iPS). They could be exceptional 
potential clinical tools useful for any muscle degenerations treatment even though further studies 
might be required in order to avoid any risk (Berardi et al., 2014).  
 
 
Read-through of Stop-Codon strategy 
Another pharmacological strategy for DMD pathology has been developed as that the 10-15% of 
patients showed a non-sense mutation (premature stop-codon) responsible for the release of a 
truncated, and a non-functional dystrophin protein. To overcome this obstacle, small molecules 
called aminoglycosides have been used as their capacity to bind the decoding site of ribosomal 
RNA. Aminoglycosides change the mRNA conformational structure by allowing the substitution of 
mutation-induced stop codon with a single amino acid by ribosomal subunit at the aminoacyl 
transfer RNA acceptor site. The result is the production of a full-length dystrophin protein and an 
increase read-through of the premature stop-codon (Partridge, 2011; Finkel, 2010). Different 
aminoglycosides are synthetized with the purpose to create molecules poor of side effects. In vitro 
and in vivo studies carried out in mdx mice by using aminoglycoside Gentamicin showed its ability 
to suppress stop- codon and to enhance the dystrophin expression (Barton-Davis et al., 1999). Thus, 
Gentamicin has been tested on DMD patients carrying a stop-codon. They were treated weekly or 
twice weekly for six months. After 6 months, 3 out 12 patients showed 13 to 15% of normal 
dystrophin levels (Malik et al., 2010). Another compound developed was Ataluren (PTC124), an 
orally bioavailable drug with read-through activity. Pre-clinical studies in mdx mice revealed its 
ability to restore dystrophin up to 20% of normal levels but for a limited time (Welch et al., 2007). 
The safety of Ataluren has been established in humans by phase I study in healthy volunteers 
(Hirawat et al., 2007). This result leads to a phase IIa proof-concept study in patients affected by 
DMD and BMD followed by the IIb phase. 
 
 
Utrophin treatment  
Utrophin, an orthologue of dystrophin, has a structural organization and binding properties similar 
to dystrophin. After birth, when muscle becomes mature, Utrophin is replaced by dystrophin. The 
expression of Utrophin depends on the promoter A and the promoter B (Burton et al., 1999). The 
promoter A allows the Utrophin expression in skeletal muscle; instead the B promoter is 
responsible for the expression of Utrophin in endothelial cells (Weir et al., 2002). The up-regulation 
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of Utrophin in adult and dystrophic muscle represents one of the first strategies realized in order to 
replace dystrophin protein. Several studies indicated that in muscle fibers of mdx mice the increase 
of Utrophin could ameliorate the dystrophic condition by restoring the sarcolemma expression of 
the dystrophin-associated protein complex (DAPC) (Tinsley et al., 1996; Gilbert et al., 1999). 
Therefore, by high-throughput screening studies, small molecules have been created with the 
purpose to increase Utrophin expression. An example of these molecules is Hergulin. This molecule 
acts by Utrophin promoter A via the N-box motif and L-arginine so that it is able to increase the 
production of nNOS followed by an increase in Utrophin expression (Miura et al., 2006).  
Thus, other approaches such as the overexpression of the small GTP-ase Rho and the inhibition of 
Calpain have been adopted in mdx mice, but they are not able to increase the protein levels in order 
to give the complete recovery of the dystrophic phenotype (Gauthier and Kerrache, 2009). 
Moreover, also the glucocorticoids have been tempted to stabilize the Utrophin in muscle (Lu et al., 
2008).  
 
 
Nitric Oxide therapy in Muscular Dystrophies 
The intracellular messenger Nitric oxide (NO) is expressed in skeletal muscle and represents an 
important regulatory signal for different physiological effects in the muscle such as force 
generation, muscle mass, muscle repair from injury, fatigue, blood flow and oxidative stress 
(Stamler and Meissner, 2001; De Palma and Clementi, 2012). In skeletal muscle NO synthesis is 
catalyzed by the nNOSμ enzyme, which belongs to the DGC complex (Miglietta et al., 2012). In 
DMD dystrophy, the absence of dystrophin is responsible for the loss of nNOSμ enzyme and hence 
for NO, contributing significantly to dystrophic pathology (Lai et al., 2009; Li et al., 2011). In this 
scenario, various pharmacological approaches aimed at regulating NO supply to the skeletal muscle 
have arisen (Miglietta et al., 2012). Results from therapies based on the administration of NO 
donors only, did not show persistent beneficial effects (Voisin et al., 2005; Marques et al., 2005). In 
particular, two NO donors, the organic nitrate isosorbide and molsidomine have been investigated. 
While the former alone was no effective, the latter showed a moderate long-term efficacy (Buono et 
al., 2012). The reasons of these different effects are still poorly understood so the realization of 
alternative strategies for an effective pharmacological therapy has been necessary. The use of NO 
donation in combination with anti-inflammatory drugs has been the subsequent approach tested. 
The first study on mdx mice provided the use of L-arginine (NO donor) associated with the 
corticosteroid Deflazacort. Results showed functional recovery on muscle voluntary exercise 
(Archer et al., 2006). Then, other variants of this approach by using non-steroidal anti-
INTRODUCTION 
28 
 
agents (NSAIDs) have been tested. An example is given by the use of isosorbide dinitrate in 
combination with ibuprofen, in which the NO-donating agent is a different molecular entity respect 
to the anti-inflammatory drug; another example consists in a strategy in which the two activities are 
associated in a single molecular entity represented by a new class of NO-donating drugs called 
cyclooxygenase (COX)-inhibiting NO donors (CINODs) (Wallace et al., 2009). Both these 
approaches reported beneficial effects in mouse models of muscular dystrophies without significant 
side effects (Uaesoontrachoon et al., 2014). The combination of isosorbide dinitrate with ibuprofen 
was also tested in a cohort of adult patients affected by DMD, Becker and Limb-Girdle dystrophies. 
The results demonstrated good safety and tolerability profiles of the long-term co-administration of 
the drugs and of notice, the side effects reported were few and transient. Moreover, other results 
revealed also a good efficacy of the drugs demonstrated by an amelioration of motor function 
measure scale (D’Angelo et al., 2012). Until now, the best compound belonging to the CINOD class 
is Naproxcinod that has both anti-inflammatory and analgesic effects (Schnitzer et al., 2005). 
Initially, it was developed for the osteoarthritis. Upon absorption, Naproxcinod is metabolized to 
Naproxen and the NO-donating moiety, which is able to release NO by enzyme bioactivation. In 
2015, Miglietta et al., demonstrated that Naproxcinod treatment improves skeletal muscle force 
after 1 month of administration in mdx sedentary mice. Of importance, they also reported that the 
same effect of Naproxcinod was maintained after 6 months of treatment also in animals forced to 
exercise. Moreover, long-term treatment with Naproxcinod reduces diaphragm inflammatory 
infiltrates. For all these reasons, Naproxcinod has been currently considered the ideal therapeutic 
option among CINODs for DMD treatment (Miglietta et al., 2015). 
 
Figure 10: Approaches for muscular dystrophies (Berardi et al., 2014; Frontiers in Physiology).   
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Chapter 3: Sphingolipids and Acid Sphingomyelinase 
3.1 Sphingolipids in cell signaling 
Sphingolipids (SLs) are ubiquitous, membrane components of all eukaryotic cells and the major 
constituents of lipoproteins. The term ‘sphingolipid’ refers to a number of lipids synthesized in the 
endoplasmic reticulum (ER) from non-sphingolipid precursor and defined by their long-chain 
sphingoid base backbone (e.g. sphingosine), an amide-linked, long chain fatty acid and one of 
various polar head groups. Modification of these head groups is what gives rise to the vast family of 
sphingolipids. Sphingolipids are mainly present at the level of the plasma membrane, where they 
play an important role in defining its physical and chemical properties. Although the diversity of 
structure and function the creation and destruction of sphingolipids are regulated by common 
synthetic and catabolic pathways (Deigner et al., 2007; Gault et al., 2010).  
First discovered by J. L. W. Thudichum in 1876 for a long time SLs were considered to play 
primarily structural roles in membrane formation (Bartke and Hannun, 2008). However, SLs do not 
just play a structural role in membrane bi-layer with rather inert metabolism, in contrast, some of 
the intermediate molecules of its metabolism (i.e. Ceramide, Glucosil-ceramide and Sphingosine-1- 
phosphate) are important signaling molecules involved in the modulation of various and 
fundamental key cellular processes such as proliferation, differentiation and induction of apoptosis 
(Bleicher and Cabot 2002; Payne, Milstien et al., 2002; Hannun and Luberto, 2004).  
Hence, structure, recognition and signal transduction can be considered the three crucial aspects in 
the sphingolipid actions. The mechanisms of sphingolipids-mediated signal transduction are 
characterized by an extreme complexity (Riboni, Prinetti et al., 1995; Huwiler, Kolter et al., 2000). 
Furthermore, a significant body of experimental evidence points to an important role for 
sphingolipid mediators in the inflammatory process (Chalfant and Spiegel, 2005; El Alwani et al., 
2006).  
 
Enzymes in the sphingomyelin cycle  
 
Sphingomyelin (SM) is the most abundant sphingolipid with an important structural role in the 
integrity of the plasma membrane (Villani et al., 2008).  
Sphingomyelin synthase (phosphatidylcholine/Ceramide–PCh transferase) is the enzyme 
responsible for the production of SM through the transfer of a phosphocholine head group from 
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phosphatidylcholine on to the primary hydroxyl group of Ceramide, an important bioactive 
molecule, generating diacylglycerol (DAG) as an additional product of the reaction (Ullman et al., 
1974; Voelker et al., 1982). Therefore, the biological importance of Sphingomyelin synthase resides 
not only in the biosynthesis of SM but also in the regulation, in opposing directions, of the levels of 
Ceramide (Luberto et al., 1998). Biochemical studies reported the Sphingomyelin synthase activity 
in the Golgi and residual activity in other cellular compartments such as plasma membrane 
(Marggraf et al., 1981; Futerman et al., 1991). The major substrates of Sphingomyelin synthase are 
Ceramide and Phosphatidylcholine; however, the rate-limiting factor in the Golgi apparatus seems 
to be the availability of ceramide substrate.  
An alternative pathway to the formation of Sphingomyelin can take place through the addition of 
phosphoethanolamine to Ceramide followed by single methyl transfer to form the choline head 
group. Most notable component of Sphingomyelin cycle is Ceramide. Ceramide is a bioactive 
sphingolipid that can be considered as a metabolic hub in the sphingolipid biosynthesis and 
catabolism (Hannun and Obeid, 2008). Multiple metabolic pathways are responsible for Ceramide 
formation and among these de novo biosynthetic pathway and the Sphingomyelinase (SMase) 
pathway have been deeply studied (Kitatani et al., 2008).  
De novo sphingolipid synthesis begins at the cytosolic leaflet of the endoplasmic reticulum where a 
coordinately set of four enzyme groups generate ceramides of different acyl chain lengths from non-
sphingolipid precursors (Gault et al., 2010). The first step is catalyzed by the serine palmitoyl 
transferase (SPT) complex which condenses the amino acid serine and the fatty acid palmitate to 
form 3-keto-dihydrosphingosine. The carbonyl group of 3-keto-dihydrosphingosine is then reduced 
to form dihydrosphingosine, and the enzyme (dihydro) ceramide synthase (CerS) then adds a fatty 
acid chain (the acyl chain) by N-acylation to form dihydroceramide. Finally, desaturation of the 4, 5 
carbon-carbon bond on the sphingoid backbone generates Ceramide (Airola et al., 2014). Ceramide,  
generated is transported to the Golgi complex, where it serves as a substrate for the production of 
complex sphingolipids (Gault et al., 2010). 
Ceramide can be also generated by the hydrolysis of sphingomyelin by the activation of the 
catabolic enzymes sphingomyelinases (SMases) (Marchesini et al., 2004). Five distinct enzymes 
have been identified based upon their pH optima, cellular localization and cation dependence. The 
neutral SMase (N-SMase) membrane-bound Mg++ independent sphingomyelinase and the 
lysosomal acid pH-optima sphingomyelinase (A-SMase) have been the most studied for their roles 
in ceramide synthesis. These enzymes break down sphingomyelin to produce ceramide and 
phosphorylcholine. Accumulation of ceramide in cellular membranes results in the formation of 
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lipid rafts and functional clustering of surface receptors (Deigner et al., 2007). Currently, evidence 
addresses the importance of A-SMase to the transmembrane signaling.  
 
 
 
 
 
 
 
Figure 11: Metabolism of sphingolipids (Norishi Ueda, 2014; International Journal of Molecular Sciences). 
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3.2 Sphingolipids in inflammation  
 
As sphingolipids are not considered the inert molecules, they have been extensively studied and 
recent data from literature suggest their importance in complex processes such as the inflammatory 
response. The involvement of a specific sphingolipid mediator or another depends on the cellular 
context but this new finding allows new pharmacological interventions. Each sphingolipid has a 
specific mode of action so that each one influences the inflammation in different ways (Chalfant 
and Spiegel, 2005; El Alwani et al., 2006). Sphingolipids are involved in specific phases of acute 
inflammation such as migration of immune cells, recognition of exogenous agents, activation and 
differentiation of immune cells (Grösch et al., 2018).  
Among sphingolipids, ceramide, ceramide-1 phosphate (C1P) and sphingosine-1 phosphate (S1P) 
represent the sphingolipid metabolites mainly implicated in the inflammatory pathways.  
The role of ceramide in the inflammatory process has been reported for the first time from studies 
carried out on the intracellular effects of the inflammatory cytokine tumor necrosis factor D (TNF-
D) (Kim et al., 1991; Mathias et al., 1991). TNF-D activates Acid Sphingomyelinase, which is able 
to produce ceramide. The ceramide production results in the activation of the inflammatory pathway 
by nuclear factor- NE (NF-NE) gene transcription (Nixon, 2009). NF-NE is a pro-inflammatory 
transcription factor responsible for the induction of different genes that encode cytokines and 
chemokines such as interleukin 1E (IL-1E), IL-6, IL-8, monocyte chemoattractant protein-1 
(MCCP1) and pro-inflammatory enzymes such as COX-2 (Xiao and Ghosh, 2005). Up to now, the 
capacity of ceramide in regulating the inflammatory process in all cell types is still unclear but data 
from literature indicate its possible in vivo role. Indeed, Teichgärber et al., demonstrated the 
importance of ceramide in the transgenic mouse model of cystic fibrosis in which an accumulation 
of membrane ceramide is responsible for the pulmonary inflammation.  
The role of C1P in the inflammatory signaling is less clear compared to ceramide action. Data from 
studies carried out in macrophages and in lung cancer cells revealed the involvement of C1P in the 
activation of cytosolic phospholipase A2 (cPLA2) (Pettus et al., 2003; Pettus et al., 2004). 
Moreover, ceramide kinase and C1P are able to inhibit TNF-D post-translational modification by 
TNF-D converting enzyme (TACE) and hence the TNF-D production (Jozefowski, 2010; Loamour 
et al., 2011).  
The Sphingosine 1-phosphate is involved in different inflammatory processes and its effects depend 
on the cell type specificity. It is well known that S1P has been a pro-survival signal and a promoter 
of chemotaxis for lymphocytes (Rutherford et al., 2013; Messias et al., 2016). Hughes et al. 
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demonstrated that the treatment of LPS-stimulated primary macrophages with S1P is able to inhibit 
the development of pro-inflammatory macrophages subset (M1).  
Moreover, several recent studies highlighted the importance of S1P and S1P receptor signaling in 
pathological inflammation such as diabetic retinopathy and acute lung injury. S1P receptors are G 
protein coupled receptors and are able to mediate various functions (Hla et al., 2001). For example, 
in mast cells activation SP11 receptor is responsible for the mast cells migration and SP12 for 
degranulation (Jolly et al., 2004). A fungal metabolite FTY720 represents the potential therapeutic 
intervention able to regulate the sphingolipid effects on inflammatory process. The phosphorylation 
of FTY720 by Sphingosine Kinase (SK) has been assessed by in vivo experiments. FTY720-P is an 
agonist of S1P receptors. After binding to the S1P receptor, FTY720-P exerts its 
immunosuppressant function by sequestering lymphocytes to lymph nodes (Billich et al., 2003). 
This mechanism of action is responsible for the reduction of atherosclerosis in mice that display low 
monocyte infiltration to artery walls and inflammation (Nofer et al., 2007; Keul et al., 2007). In 
other inflammatory diseases including ulcerative colitis and inflammatory bowel disease, both in 
mouse model and in patients increased activity levels of S1P/ Sphingosine Kinase 1 (SK1) were 
found (Snider et al., 2009). In vivo studies showed that the deletion of SK protects mice from 
hepatic steatosis (Mauer et al., 2017). Indeed, high levels of SK1 were observed in mouse model 
and human patients affected by nonalcoholic fatty liver disease which correlates with the activation 
of NF-κB and the increase of pro-inflammatory cytokines and the infiltration of immune cells 
(Geng et al., 2015).  
  
 
3.3 Acid sphingomyelinase (A-SMase)  
The sphingolipid-metabolizing enzyme Acid Sphingomyelinase (A-SMase) is a key enzyme in 
sphingolipid metabolism because it catalyzes the hydrolysis of sphingomyelin (SM) to ceramide 
and poshorylcholine. A-SMase plays an important role in the ceramide-mediated signaling pathway 
(Zhou et al., 2016). Mammalian cells contain the gene for A-SMase, SMPD1, which is responsible 
for the generation of the enzyme. A-SMase is highly conserved in animals, from C. elegans to 
human, with over 35% protein sequence identities.  
The A-SMase structure is characterized by a multi-domain protein including a saposin domain, a 
proline-rich linker, a metallo-dependent phosphatase catalytic domain, and an ill-defined C-terminal 
domain (Fig. 12) (Jenkins et al., 2009). Saposin proteins are sphingolipid activator proteins that 
present lipids from membranes to the active sites of various enzymes in an acidic cellular 
compartment (Kolter et al., 2005). The saposin domain in A-SMase is sufficient to support the 
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hydrolysis of sphingomyelin without external saposin proteins (Paton et al., 1992; Bradovà et al., 
1993). A-SMase was originally identified as a cation–independent hydrolase contributing to the 
catabolism of sphingomyelin in lysosome compartment. Subsequently, studies have indicated an 
enzyme metallo-dependence and a localization limited not only to lysosomes. Indeed, the enzyme is 
also secreted from vascular endothelial cells and macrophages through the Golgi secretory pathway 
as a Zn++ dependent enzyme (Marathe, Schissel et al., 1998). Upon its localization, two forms of A-
SMase originating from one gene have been reported, an intracellular lysosomal form and an 
extracellular secreted form. The lysosomal A-SMase is preloaded with zinc, while the secreted form 
requires exogenous zinc (Schissel SL, et al., 1996).  
 
 
 
Figure 12: A) Primary structure of A-SMase polypeptide. B) Stylized conformation of mature A-SMase (Russel 
W., 2009; Cell Signal.).  
 
 
 
 
Figure 13: Sphingomyelin degradation catalyzed by Acid Sphingomyelinase activity (Zhou et al., 2015; Nature 
Communications).  
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The cDNA and complete gene-encoding mouse A-SMase has been isolated. Comparison with the 
human sequence shows 81% sequence identity at cDNA level and 82% at the protein level. 
Homology is reduced in the N-terminal region, especially in the presumed signal peptide. The six-
exon gene structure is similar to the human one; the murine enzyme has six potential N-
glycosylation sites, which prevent the enzyme from proteolytic degradation in the lysosome 
(Newrzella and Stoffel, 1996). Moreover, A-SMase has a mannose 6-phosphate residue that is 
required for lysosomal targeting of the enzyme via the mannose 6-phosphate receptor (Newrzella 
and Stoffel, 1992).  
Studies performed in COS-1 cells transfected with A-SMase cDNA, revealed three major forms of 
75, 72 and 57 kDa generated from the same nascent polypeptide derived from a single processed 
transcript (Ferlinz, Hurwitz et al., 1994). After deglycosylation they are reduced in size of 64, 61 
and 47 kDa, respectively. The 75kDa form is the pre-polypeptide, which is found in the 
endoplasmic reticulum. The enzyme precursor is represented by the second form of 72kDa obtained 
by cutting a possible signaling sequence of 4kDa. After cutting, the precursor is transported to the 
endo/lysosomal compartments where it is processed to its mature form of 70kDa (Hurwitz, Ferlinz 
et al., 1994). Then, the mature enzyme is degraded to an inactive form of 52kDa.  
Upon stimulation, A-SMase is relocated from intracellular organelles to the outer leaflet of the 
plasma membrane, where it is able to hydrolase the SM, localized within lipid raft micro domains, 
to ceramide. Lipid rafts are dynamic structures formed by clustering of sphingolipids and 
cholesterol by functioning as platforms for signal transduction and protein sorting (Simons and 
Ikonen, 1997).  
Stimulation with CD95 (Fas) ligand rapidly induces the translocation of A-SMase from lysosomal 
to the outer leaflet of the plasma membrane. Moreover, ceramide produced by A-SMase is an 
important component of the lipid micro domains and it is essential for CD95 signaling and the 
induction of apoptosis (Grassme, Jekle et al., 2001).  
Furthermore, A-SMase on the cell surface is essential for the clustering of CD40 (Grassme, 
Jendrossek et al., 2002), Fcy receptor II (Abdel Shakor, Kwiatkowska et al., 2004), CD20 and 
TRAIL receptor (Martin, Philips et al., 2005). Genetic alterations in A-SMase lead to A-SMase 
deficiency (ASMD) and have been linked to Niemann–Pick disease types A and B (Zhou Y-F et al., 
2016). The mapping of mutations from Zhou Y et al. study revealed that 82% of the mutations are 
located in the catalytic domain, resulting in 21.6% mutation rate in protein sequence. In contrast, 
the mutation rates in the saposin, proline-rich linker, and C-terminal domains are no >11% (Fig. 
14). 
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Figure 14: Distribution of mutations on hA-SMase sequence (Zhou et al., 2015; Nature Communications). 
 
 
 
3.4 Acid Sphingomyelinase and inflammation 
The involvement of A-SMase in the lysosomal storage disorder Niemann-Pick disease (NPD) is 
well known since 1960, when for the first time researchers reported that A-SMase deficiency was 
responsible for the accumulation of sphingomyelin in lysosomes and late endosomes (Brady et al., 
1966). Subsequent investigations highlighted the important role of the hydrolase in mediating cell 
signaling by generating ceramide from the membrane lipid sphingomyelin. As ceramide is a 
bioactive lipid and a well-known mediator of stress signals and pro-inflammatory response, the A-
SMase activation has been considered the key event in a variety of pathophysiological processes 
including inflammation, oxidative stress and cytokines release in common human diseases 
(Schuchman, 2010). In recent years, it has become increasingly evident that in the pathophysiology 
of many human diseases the effect of the imbalance of A-SMase activity may be related to 
inflammation. High levels of A-SMase activity have been found in various diseases characterized 
by a strong inflammatory component such as Alzheimer’s and Parkinson’s diseases (Haughey, 
2010), diabetes (Opreanu et al., 2011), atherosclerosis (Deulin et al., 2008), chronic heart failure 
(Schissel et al., 1998) and steatohepatitis (Garcia-Ruiz, 2015).  
Since A-SMase is responsible for the ceramide production at the cell surface, it is responsible for 
the plasma membrane reorganization. This ability gives rise to the important role of the enzyme in 
cell signaling. Moreover, A-SMase is a mediator of different stimuli, such as cell death receptor 
activation, radiations and chemotherapeutic drugs. An increase of A-SMase activity has also been 
found in cancer, a disease characterized by abnormal cell growth. Interestingly, Assi et al., 
demonstrated the role for A-SMase in the modulation of tumour immune microenvironment.  
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A-SMase plays also a role in other common pathologies such as inflammatory bowel diseases (IBD) 
and pulmonary diseases.  
In patients affected by IBD, macrophages play a critical role in the pathology and they are 
responsible for the production of inflammatory cytokines such as IL-1β, TNF-α, and IL-6 (Rogler et 
al., 1998). These cytokines as well as other stress stimuli are able to activate A-SMase and hence to 
increase the ceramide levels. High levels of ceramide lead to an increase of expression of various 
inflammatory genes by the activation of pro-inflammatory NF-κβ transcription factor (Spiegel et al., 
1996). So, the attenuation of inflammatory response by suppressing A-SMase activity and hence the 
ceramide signaling, has been tested, but further studies are needed in order to better understand the 
ceramide metabolic pathways involved.  
In the inflammatory context, the hydrolase A-SMase has been considered a potential therapeutic 
target also in lung injury and in other conditions related to the pulmonary functions (Uhlig et al., 
2013). Studies carried out in lung injury model by Okuro et al., showed that the inhibition of A-
SMase suppressed the up-regulation of NF-κβ activity with a reduction of pro-inflammatory 
cytokines IL-1β, TNF-α, and IL-6. These findings suggest that the inflammatory response could be 
regulated by A-SMase via NF-κβ.  
Although this evidence requires further studies they represent the beginning of a complex study 
related to the inflammatory process and its new possible targets belonging to the sphingolipids 
class.  
 
Figure 15: Schematic representation of Acid Sphingomyelinase  involvement in inflammatory related diseases 
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AIM OF THE STUDY 
 
This project arise from the idea to investigate the functional role of the sphingolipid-metabolizing 
enzyme A-SMase in acute and chronic muscle damage with the purpose to better understand its role 
in the establishment of muscle inflammation and in the subsequent skeletal muscle regeneration 
process so that this protein may be proposed as possible therapeutic target. 
The first aim of the study is the investigation of A-SMase expression in the intricate inflammatory 
process following cardiotoxin induced-acute muscle damage. To this end, we use wild type and A-
SMase knockout mice in order to elucidate its role in the signaling of muscle regeneration. Thus, we 
focus our attention on the action of A-SMase on the proliferation and differentiation of muscle stem 
cells (satellite cells) before and after muscle damage. The inflammatory response in muscle damage 
is a coordinated process in which macrophages play a critical role in the resolution of inflammation 
(Mounier et al., 2013) through a delicate biphasic transition from pro-inflammatory (M1) to anti-
inflammatory phenotype (M2). Currently, the signaling pathways responsible for the macrophages 
polarization are poorly understood (Mounier et al., 2013) so we investigate whether A-SMase might 
influence the balance between the M1 and M2 macrophage subsets and hence the muscle repair 
after injury.  
The second aim of the study is the evaluation of the possible role of A-SMase in the pathogenesis of 
Duchenne Muscular Dystrophy (DMD). In particular, we focus our attention on the role of A-
SMase in the establishment of inflammation during the progression of the disease.  
All the experiments are carried out comparing wild-type mice to the mdx mice, a mouse model of 
DMD, used in order to deepen the involvement of A-SMase in DMD pathogenesis.  
Overall, we aim at identifying A-SMase as a potentially targetable player not only in DMD but also 
in various muscle-wasting diseases.  
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MATERIALS AND METHODS 
 
Mice and animal care  
Experiments were performed on (C57J/6N) A-SMase knockout (A-SMase-KO), mdx (C57BL/10-
mdx) and wild type (WT) (C57BL/6J) mice. Animals were handled in accordance with the Italian 
law on animal care (D.L. 26/2014) and the European Directive (2010/63/UE). The mice were 
housed in an environmentally controlled room (23°C ± 1°C, 50% ± 5% humidity) with a 12-hour 
light/dark cycle and provided food and water ad libitum. The Ethics Committee of the University of 
Milan also approved the experimental protocols. All efforts were made to reduce both animal 
suffering and the number of animal used.  
 
 
Acute muscle damage  
A-SMase-KO and WT mice were anesthetized and subsequently injected with Cardiotoxin (CTX) 
from Naja Mossambica mossambica (Sigma- Aldrich). CTX was dissolved in sterile saline to a 
final concentration of 15µM and then injected in Tibialis Anterior (TA) muscles from 2-months-
old. In total, 50µl of CTX were injected with a 27 Gauge needle into one TA muscle. Mice were 
sacrificed at 1, 3, 5, 7,14 and 21 days after injury and the TA muscles were harvested and analyzed 
at different time points after injury.  
 
 
Naproxcinod treatment 
Male mdx mice (n=5) were treated with Naproxcinod (30 mg/Kg) for 6 months starting at 5 weeks 
of age. The compound was administered daily in the diet (Mucedola, Milano, Italy), and the same 
diet without drug was given to control mdx mice (n=5). Following 6 months of treatment Acid 
Sphingomyelinase mRNA expression and activity have been detected in Tibialis Anterior of mdx 
animals.  
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Quantitative Real-Time PCR analysis  
Total RNA was isolated by phase separation in PureZOL™ reagent (Bio-Rad) according to the 
manufacturer’s instructions. After solubilisation in RNase-free water, total RNA was quantified by 
the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Total RNA (1µg) 
was retro-transcribed by using iScript™ Reverse Transcription Supermix (Bio-Rad). PCR was 
performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, 1725271) and the 
CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA). All reactions were run 
as triplicates by using 2µl of cDNA and the GoTaq Green Master Mix (Promega). RPL38 
(Ribosomal Protein L38) and RPL32 (Ribosomal Protein L32) have been used as housekeeping for 
normalization by using the 2−ΔΔCT formula. The primers pairs designed for RTqPCR analysis are 
listed in the table below. 
 
MATERIALS AND METHODS 
41 
 
 
                                Tab 1: Primers used for quantitative RT real-time analyses 
NAME FORWARD PRIMER REVERSE PRIMER 
CCL2 5'-AGGTGTCCCAAAGAAGCTGTA-3' 5'-ATGTCTGGACCCATTCCTTCT-3' 
CCL7 5'-GCTGCTTTCAGCATCCAAGTG-3' 5'-CCAGGGACACCGACTACTG-3' 
CCR2 5'-ATCCACGGCATACTATCAACATC-3' 5'-CAAGGCTCACCATCATCGTAG-3' 
SMPD1 5'-TGGGACTCCTTTGGATGGG-3'’ 5'-CGGCGCTATGGCACTGAAT-3' 
CD80 5'- AGTTTCTCTTTTTCAGGTTGTGAA-3' 5'-CACCCGGCAGATGCTAAAGA-3' 
CD163 5'-CTCCTGTGGACTCTGAAGCG-3' 5'-CTCTGAATGACCCCCGAGGA-3' 
CD206 5'- ATGGATTGCCCTGAACAGCA-3' 5'-TGTACCGCACCCTCCATCTA-3' 
IL-1β 5'-CCCTGCAGCTGGAGAGTGTGGA-3' 5'- TGTGCTCTGCTTGTGAGGTGCTG-3' 
CD86 5'-CTTACGGAAGCACCCACGAT-3' 5'-TGTAAATGGGCACGGCAGAT-3' 
IL-10 5'-GCTCTTACTGACTGGCATGAG-3' 5'-CGCAGCTCTAGGAGCATGTG-3' 
TNF α 5'-CCCACGTCGTAGCAAACCACC-3' 5'-TCGGGGCAGCCTTGTCCCTT-3' 
TGF β 5'-AAACGGAAGCGCATCGAA-3' 5'-GGGACTGGCGAGCCTTAGTT-3' 
IGF 1 5'-GTGTGGACCGAGGGGCTTTTACTTC-3' 5'- GCTTCAGTGGGGCACAGTACATCTC-3' 
F4/80 5'-TGACTCACCTTGTGGTCCTAA-3' 5'-CTTCCCAGAATCCAGTCTTTCC-3' 
iNOS 5’GTTCTCAGCCCAACAATACAAGA-3’ 5’-GTGGACGGGTCGATGTCAC-3’ 
Myogenin 5'-GACCCTACAGACGCCCACAATC-3' 5'-ACACCCAGCCTGACAGACAATC-3' 
MyoD 5'- CTGGCGCCGCTGCCTTCTAC-3' 5'- GGCCGCTGTAATCCATCATGCCA-3' 
Arginase 1 5'-CTCCAAGCCAAAGTCCTTAGA-3' 5'-AGGAGCTGTCATTAGGGACAT-3' 
RPL38  5’-GAAGAATGCCAAGTCTGTCAA-3’ 5’-GAGGGCTGGTTCATTTCAGA-3’ 
RPL32  5’-TTAAGCGAAACTGGCGGAAAC-3’ 5’-TTGTTGCTCCCATAACCGATG-3’ 
IL-6 5'-TAGTCCTTCCTAGCCCAATTTCC-3' 5'-TTGGTCCTTAGCCACTCCTTC-3' 
MyHC II 5’AAGCGAAGAGTAAGGCTGTC3’ 5’GTGATTGCTTGCAAAGGAAC3’ 
MyHC IV 5’ACAAGCTGCGGGTGAAGAGC3’ 5’CAGGACAGTGACAAAGAACG3’ 
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Protein Isolation and Western Blotting 
For protein analysis, muscles from mice were harvested and homogenized with Ultra-Turrax (Ika 
Werke GmbH & Co. KG, Staufen Germany / Deutschland) in a protein lysis buffer containing 
20mM Tris-HCl (pH 7.4), 10 mM EGTA, 150 mM NaCl, 1% Triton X-100 (Sigma-Aldrich, X100), 
10% glycerol, 1% SDS (Sigma Aldrich, L3771) supplemented with a cocktail of protease and 
phosphatase inhibitors (cOmplete and PhosSTOP; Sigma-Aldrich, 04693116001 and PHOSS-RO).  
Proteins concentration was determined by Bio-Rad protein assay (Bio-Rad, 500-0006). Thirty to 
fifty µg of total protein were loaded on 4-20 % polyacrylamide precast gels (Criterion TGX Stain-
free precast gels; Bio-Rad, 5678094). Proteins were transferred onto a nitrocellulose membrane 
using a Trans-Blot Turbo System™ (Bio-Rad, Hercules, CA) and Transfer pack™ (Bio-Rad, 
1704156). The antibodies used for the analysis were rabbit polyclonal anti-GAPDH (1:3000; Santa 
Cruz Biotechnology), rabbit anti A-SMase (1:500) and mouse anti Myogenin (1:100).  
Bands were visualized using HRP-linked secondary antibodies (Bio-Rad) and the Clarity Western 
ECL substrate (Bio-Rad, 1705061), with ChemiDoc MP imaging system (Bio-Rad, Hercules, CA). 
Image Lab software (Bio-Rad, Hercules, CA) was used for bands quantification and densitometry 
analyses. 
 
 
Histological analysis of skeletal muscle 
Skeletal muscle damage and repair were evaluated by Hematoxylin and Eosin (H&E) staining. 
H&E stains the cytoplasm in pink and the nuclei in dark purple and gives information on the 
morphology of the analysed muscle tissue in order to detect qualitative and quantitative alterations.  
The fresh muscles were mounted on cork circles using tragacanth gum and routinely frozen in 
liquid N2-cooled isopentane (Sigma-Aldrich). Muscles were sectioned on a cryostat at 10μm 
thickness and placed on Superfrost™ glass slides. Frozen sections of TA muscle were fixed in 4% 
paraformaldehyde (Sigma-Aldrich, P6148) (pH 7.4) for 10 minutes at 4°C, washed for three times 
with deionized water and stained with Eosin 1% for 10 minutes. After three washes with deionized 
water, sections were stained with Hematoxylin for 5 minutes followed by three washes with 
deionized water at room temperature. Then, muscle sections were dehydrated in series of Ethanol 
dilutions from 70% to 100% (2 minutes for each dilutions), passed though Xylene for 20 minutes, 
mounted with Eukitt ® (Sigma- Aldrich) and coverslip.  
 
MATERIALS AND METHODS 
43 
 
Images were acquired using a bright-light microscope; digital camera and image capture software. 
Histological features were identified manually and quantified using Image J analysis software. For 
quantitative analysis, cross-sectional area (CSA) was measured in Laminin-Hematoxylin stained by 
drawing around the entire cross-section area of the muscle fibre; central nucleation analysis and the 
number of fibers were counted in H&E stained (Bio-Optica) by using Image J software.  
 
 
Masson’s Trichrome  
Masson’s Trichrome is used to discriminate collagen fibers from muscular tissues. To this end, 
cryostatic sections (10μm) of untreated TA muscles from WT and A-SMase-KO mice were placed 
on Superfrost™ glass slide and stained with Masson Trichrome Kit (Bio-Optica Milano s.p.a). This 
staining demonstrates: 
• Nuclei and Gametes (black) 
• Cytoplasm, keratin, muscle fibres, acidophil granules (red)  
• Collagen, mucus, basophil granules of hypophysis (blue)  
• Delta cells granules of hypophysis (blue) 
• Erythrocytes (yellow) 
 
 
Non-specific Esterase Assay 
Non-specific esterase assay (NSA kit; 30-30122LY; Bio-Optica Milano s.p.a.) is used to identify 
macrophages infiltration in mouse skeletal muscle. To this end, cryostatic sections (10μm) of TA 
and Diaphragm muscles from WT and mdx mice were placed on Superfrost™ glass slide and 
stained with NSA kit  (Bio-Optica Milano, s.p.a). This staining demonstrates: 
- Angular atrophic fibers                           (beige)  
- Neuromuscural junction                          (brown)  
- Lipofuscin brown Lysosomal activity    (brown)  
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Immunofluorescence  
For immunofluorescence, frozen 10μm cross-sections of muscle were fixed with paraformaldehyde 
4% for 20 min at 4 °C, blocked and permeabilized with 10% goat serum (NGS; Vector 
Laboratories, S-1000), 0.1 % Triton X-100 (Sigma-Aldrich, X100) in DPBS (EuroClone) for 1hour 
at room temperature. Then, sections were incubated with primary antibody Laminin (1:250, Abcam) 
for 1 hour at 4°C. The primary antibody was diluted in PBS, 0.1% Triton X-100 and 10% goat 
serum. After incubation with the appropriate fluorescent-labelled secondary antibodies (donkey 
anti-rabbit IgG H+L conjugated with Alexa Fluor® 488, 1:5000), nuclei were counterstained with 
Hoechst 33342 and slides were finally mounted with the ProLong Gold antifade reagent (all 
products from ThermoFisher Scientific, Walthan, MA, USA). 
For myogenic precursor cells staining, cells were fixed with 4% PFA for 10 min at room 
temperature and permeabilized by 0.1% TritonX-100 in DPBS for 5 minutes at room temperature. 
Cells were blocked in blocking solution (10% NGS in DPBS) and then, labeled with specific 
primary antibodies prepared in blocking solution, and incubated at 4°C overnight. Then, cells were 
incubated with Alexa Fluor-conjugated antibodies in blocking solution for 1 h at room temperature.  
 
 
Flow Cytometry 
Fluorescence activated cell sorting (FACS) is an assay in which single cell properties either 
physical or chemical are simultaneously analysed in a fluid stream system and used to separate a 
heterogeneous sample into distinct groups of cells. 
In order to isolate muscle cell from immune cell populations, injured TA muscles from WT and A-
SMase-KO mice were harvested, minced and digested in a freshly prepared Dispase and 
Collagenase (type II) for 40 minutes at 37°C. Disaggregation was stopped with 10% fetal bovine 
serum and cells filtered through a 70µm cell strainer (Miltenyi Biotec). To determine the expression 
of cell surface markers in both mouse model, a fluorescence-activated cell sorter analysis was 
performed: collected cells were washed with PBS supplemented with 2% FBS and incubated with 
different antibodies for 30 minutes at 4°C. After washing, the samples were analysed by using 
Gallios Flow Cytometer (Beckman-Coulter, Brea, CA, USA) and the software FCS Express 4 (De 
Novo System, Portland, OR, USA).  
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Satellite cells were identified as an enriched population of α7-Integrin-PE (AbLab) and CD34-
Alexa Fluor (BD Pharmingen™) double positive cells and CD45-PE-Cy7, CD31-PE-Cy7, CD80-
FITC, CD86-FITC, CD14-FITC (eBioscience) and Sca1-FITC (BD Pharmingen™) negative cells.  
For macrophage analysis cells were stained with CD45-PE-Cy7, CD80-FITC (eBioscience), F4/80-
PE (Miltenyi Biotec) and CD206 Alexa Fluor647 (BioLegend).  
 
 
Myogenic precursor cells isolation and culture conditions  
Murine myogenic precursor cells (MPCs) were obtained from fore limbs and hind limbs of neonatal 
A-SMase-KO and WT mice (5-7d old). Muscle mass was minced and digested in Dispase® (1.867 
units/mg, Gibco®) and collagenase II (0.2% Sigma-Aldrich) for 40 minutes at 37°C. Satellite cells 
were generated by culture in Dulbecco’s Modified Eagle’s Medium (DMEM) (EuroClone 
ECB7501L) supplemented with 20% fetal bovine serum (EuroClone, ECS0180L), 3% chick 
embryo extract (custom made), 10 ng/ml basic fibroblast growth factor (PeproTech, 100-18B) and 
1% penicillin-streptomycin (EuroClone, ECB3001D/1) in culture dishes coated with Matrigel (BD 
Biosciences, 354234) at 37°C with 5% CO2. To observe in vitro differentiation, MPCs were seeded 
30000 cell/cm2 and induced in DMEM containing 2% horse serum (HS) (EuroClone, ECS0090L) 
and 1% penicillin-streptomycin for 3 days. Then, cells were incubated with antibodies against 
skeletal muscle myosin and DAPI (ThermoFisher Scientific, 62248). Fusion index, diameter of 
myotubes, number of nuclei/myotubes and myotubes ≥ 5 nuclei were calculated from three to five 
randomly chosen microscopic fields. Fusion index was calculated as the percentage of number of 
nuclei within myotubes over the total number of nuclei.  
 
 
Macrophage Primary Culture  
Macrophages were obtained from bone marrow (BM) precursor cells of WT and A-SMase-KO 
mice. Total BM was obtained from mice by flushing femur and tibiae BM with DMEM medium. 
Cells were isolated and propagated for 8 days in α-minimum essential medium (Gibco®) (37°C, 5% 
CO2 in humidified atmosphere) containing 10% fetal bovine serum (FBS) in the presence of 
100ng/mL macrophage-specific colony-stimulating factor (M-CSF, Miltenyi Biotec) to generate 
macrophages. Macrophages were activated with cytokines in order to obtain various activation 
states. Hence, adherent cells were collected and cultured in the presence of 10ng/mL M-CSF to 
form monolayers of differentiated, unpolarized macrophages. Cells were cultured for two additional 
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days in the presence of 10ng/mL IFN-γ (Miltenyi Biotec) to generate activated, polarized M1 cells 
and for 4 additional days with 10 ng/mL IL-4, IL-10 and M-CSF (Miltenyi Biotec) in order to 
generate activated, polarized M2a and M2c macrophages, respectively. Purity of differentiated 
macrophages was estimated by flow cytometry after F4/80 - PeCy7 labelling (eBioscience). Cells 
were used for various analyses.  
Figure 1: Isolation of Bone Marrow-Derived Cells, Differentiation and activation of Macrophage Primary 
Cultures (The American Journal of Pathology, Perrotta et al., 2014).  
 
- Macrophage-conditioned medium  
Macrophages were obtained by following the aforementioned standard protocol. Once the 
polarization of macrophages has been achieved, cells were washed. After washing steps, DMEM 
serum free medium was added for 24h, recovered, filtered and centrifuged in order to obtain 
macrophage-conditioned medium. Co-culture experiments were performed in which macrophage-
conditioned medium was added to MPCs: for proliferation studies, macrophage-conditioned 
medium + 2.5% FBS was added to MPCs (seeded at 10000 cell/cm2 on Matrigel).  
Then, cells were incubated with rabbit anti ki-67 antibody (1:200) which were visualized using 
secondary antibody. For differentiation studies, MPCs were seeded 30000 cell/cm2 on Matrigel and 
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incubated for three days with macrophage-conditioned medium containing 2% horse serum. Cells 
were then incubated with anti-skeletal muscle myosin and subsequently visualized by using 
secondary antibody.  
  
 
A-SMase activity assay  
The A-SMase activity was determined using an acid sphingomyelinase assay kit (Echelon 
Biosciences Inc. Salt Lake City, UT) following company's instructions.  
 
- Preparation of Cell Lysate 
Cells were disrupted in ice-cold lysis buffer [150 mM NaCl, 50 mM Tris pH 7.4, 0.6% Triton X-
100, and protease inhibitor cocktail (Sigma-Aldrich)] for 20 min. Cellular debris was removed after 
centrifugation at 10,000 × g for 5 min, and 20 μg protein was used to determine A-SMase activity. 
Reaction was stopped after incubation at 37°C for 2 hrs and analyzed using a fluorescence plate 
reader at 260 nm excitation and 460 nm emission. 
 
- Preparation of Tissue Homogenate 
To the muscle tissue has been added 8x volume of ddH2O and then it was keeped on ice. 
Immediately, tissue was homogenized 3x for 15 seconds each, on medium-high power and keeped 
on ice. The homogenate was freezed-thawed once on dry ice and immediately, the tissue was 
sonicated at medium-high power for 30 seconds, allow 10 seconds break, and resume for 30 more 
seconds (total 1 minute). After sonication, 14μg total protein was used to determine A-SMase 
activity. Reaction was stopped after incubation at 37°C for 2 hrs and analyzed using a fluorescence 
plate reader at 260 nm excitation and 460 nm emission.  
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Figure 2: The Echelon Acid Sphingomyelinase Assay Kit uses a fluorogenic substrate, specific for acid 
Sphingomyelinase, to provide a sensitive and homogenous method to measure the activity of A-SMase in vitro 
 
 
Statistical Analyses 
Results were expressed as means ± SEM (standard error of the mean) of the indicative n values. All 
statistical analyses were performed using Student’s t-tests for single comparison or by one-way 
ANOVA followed by the Newman-Keuls post-test (multiple comparisons). When data are not 
normally distributed, the Mann Whitney test was used. The GraphPad Prism software package 
(Graph Software, San Diego, CA, USA) was used. 
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RESULTS 
 
Acid Sphingomyelinase is increased in cardiotoxin-induced acute damage 
 
Several lines of evidence indicate the strong relation between A-SMase expression and diseases 
with a strong inflammatory component (Haughey, 2010; Opreanu et al., 2011; Devlin et al., 2008). 
Therefore, we assessed the possible connection between muscle inflammation and A-SMase 
expression by inducing muscle injury by the injection of cardiotoxin (CTX), a useful model for 
sterile inflammation.  
Tibialis Anterior (TA) of 2-month-old wild type (WT) mice were injected with CTX and harvested 
at 1, 3, 5 and 7 days after damage (Fig. 1A). The injected TA muscles and their uninjected controls 
were processed for quantitative Real Time PCR (RTqPCR), western blot, and immunofluorescence 
analysis.  
The RTqPCR analysis showed an increase of Smpd1 mRNA, the gene that encodes for A-SMase, in 
TA muscles from WT after CTX treatment compared to those of untreated mice (Fig. 1B). Western 
blot confirmed with the RTqPCR data: the expression levels of A-SMase were much higher in 
injured-TA muscles than that in the untreated controls (UT) (Fig. 1C). Finally, the expression of A-
SMase was also evaluated by immunofluorescence on histological sections from TA muscle 
damaged in which we found a different expression pattern of A-SMase in injured muscle fibers 
compared to healthy muscle fibers (Fig. 1D).  
Taken together these findings indicate that A-SMase expression in muscle is up regulated upon 
cardiotoxin-induced acute damage and suggest a role for the protein in the process of muscle 
regeneration. 
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Figure 1: Acid Sphingomyelinase is increased in cardiotoxin-induced acute damage 
A) Schematic representation of CTX injury experiment. Tibialis Anterior of WT mice (2-month-old) were injected with 
CTX and then harvested at 1, 3, 5, and 7 days after muscle damage. B) RTqPCR analysis of the Smpd1 in TA of WT 
mice at 2-month-old. TA muscles were harvested and analyzed at 1, 3, 5, and 7 days after CTX injury. Values are 
expressed as mean ± SEM (n=6); *p<0.05. C) Western blot analysis of A-SMase protein in TA from WT mice treated 
with CTX and untreated WT mice used as control (UT) (n=2 mice for each experimental time point). The stain-free gel 
of total proteins was used as loading control. D) Injured and uninjured TA muscles of WT mice were immunostained 
with anti-A-SMase (red) antibody; nuclei were stained with DAPI (blue). The uninjured (UT) muscles were used as 
control. Scale bars, 100 µm. 
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A-SMase-/- and WT mice show similar skeletal muscle morphology  
 
To assess the possible role of A-SMase in the muscle regeneration process which follows the 
inflammatory response, we took advantage of the A-SMase knockout mice (A-SMase-/-).  
First, TA of WT and A-SMase-/- mice of 2-month-old have been harvested and analyzed by 
immuno-histological assays in order to compare the two skeletal muscle characterizations. We 
observed that the TA gross morphology and the dimensions of A-SMase-/- mice were similar to 
those of WT (Fig. 2A).  
Histological analysis by Hematoxylin & Eosin staining (H&E) did not show defects in the skeletal 
muscle of A-SMase-/- mice; Masson’s Trichrome staining also did not reveal fibrosis or 
degenerating muscle fibers in A-SMase-/- as well as in control WT muscle (Fig. 2B). Then, we 
examined muscle fiber size by measuring the cross-sectional area (CSA) of TA from WT and A-
SMase-/- mice and we did not found significant differences between the two types of mice (Fig. 2C).  
Lastly, we assessed the number of satellite cells in muscles of WT and A-SMase-/- mice. By Flow 
Cytometry analysis (FACS) a similar percentage of satellite cells was found in both types of mice 
(Fig. 2D).  
These data indicate that the loss of A-SMase neither affect the normal skeletal muscle morphology 
nor satellite cells number.  
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Figure 2: A-SMase-/- and WT mice show similar skeletal muscle morphology  
 
A) Representative image of TA of WT and A-SMase-/- mice. Scale Bar, 2μm. B) H&E and Masson’s Trichrome 
stainings of cryosections of 8-week-old WT and A-SMase-/- mice TA muscle (n=3). Scale Bar, 100 μm. C) TA muscle 
from WT and A-SMase-/- mice were immunostained with Laminin (green). The right graph indicates the mean CSA of 
TA muscle myofibers measured by using Image J software based on Laminin staining. Four animals of each genotype 
and at least 500 fibers for each animal were measured. D) The graph shows the percentage (%) of satellite cells number 
(CD45-/CD31-/CD11b-/Sca1-/α7+/CD34+ CD45 cells) in TA from WT and A-SMase-/- mice measured by FACS analysis 
(n=3).  
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Muscle satellite cells from A-SMase-/- and WT mice show similar grow and differentiation 
ability in vitro 
 
As satellite cells are able to proliferate and differentiate in response to injury giving rise to 
regenerated muscle, we wondered whether the absence of A-SMase could affect these two 
capacities of muscle progenitor cells.  
To test this, we isolated the muscle satellite cells from WT and A-SMase-/- mice and compared their 
proliferation and differentiation ability in vitro. Proliferation of myoblasts was measured after 24 
hours of culture by immunostaining with the cell cycle marker Ki67. The total number of Ki67+ 
positive cells was similar in myoblasts derived from WT and A-SMase-/- mice (Fig. 3A). Moreover, 
satellite cells were also stained for MyoD in order to better define the proliferating myoblasts (Fig. 
3B). 
Then, we analyzed the differentiation of myoblasts into myotubes in both types of mice in the 
presence of 2% horse serum (Fig. 3C). Myotubes identified by Myosin-Heavy-Chain (MF20) 
staining generated in WT and A-SMase-/- mice did not show any differences in the morphology 
assessed by the parameters such as diameter, fusion index, myotubes with more five nuclei and 
number of myonuclei per myotube (Fig. 3C).  
Moreover, also the transcript expression levels of MyoD and Myogenin fundamental for myogenic 
process and of Myosin Heavy Chain II and IV, responsible for muscle contraction, did not show any 
differences in satellite cells derived from both types of mice (Fig. 3D).  
Therefore, this evidence suggests that in vitro, muscle satellite cells isolated from A-SMase-/- mice 
show a profile of proliferation and differentiation similar to that of WT control mice. Hence, our 
findings indicate that the loss of A-SMase does not affect satellite cell proliferation and 
differentiation ability. 
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Figure 3: Muscle satellite cells from A-SMase-/- and WT mice show similar grow and differentiation ability in 
vitro 
 
A) Immunostaining for Ki67+ on WT and ASM-/- mice satellite cells after 24 hours of proliferation assay. Scale Bar, 
100µm. Ki67+ positive satellite cells of WT and ASM-/- mice are quantified (right graph) by using Image J software and 
represented using GraphPad software analysis. Values are expressed as mean ± SEM (n=3). B) Immunostaining for 
MyoD on WT and ASM-/- satellite cells. Scale Bar, 100µm. C) In vitro differentiation of myoblasts into myotubes (48h) 
of WT and ASM-/- mice. In red MF20 staining identifies the differentiated myoblasts; in blu, DAPI staining, for the 
nuclei identification. The right graphs show the quantitative analysis of differentiated myotubes parameters, such as: 
Diameter (μm); Fusion Index (the percentage of Myosin-Heavy-Chain positive cells in myotubes over the total number 
of Myosin-Heavy-Chain positive cells); Myotubes with more than 5 nuclei and the number of Nuclei per Myotube. For 
quantification, 5 images per experiment across 3 independent experiments (n=15 images) were analyzed by Image J 
software and represented using GraphPad software analysis. Values are expressed as mean ± SEM. D) RTqPCR 
analysis of MyoD and Myogenin (upper panel) and of Myosin Heavy Chain II/IV (lower panel) in myotubes of WT and 
ASM-/-mice after 24 and 48 hours of in vitro differentiation. Values are expressed as a mean ± SEM (n=8). 
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A-SMase affects muscle regeneration  
 
To explore whether A-SMase plays a role in the skeletal muscle regeneration process after induced 
damage, we performed an experiment by using the well characterized CTX induced injury model. 
To this end, TA of WT and A-SMase-/- mice were injected with CTX and then, harvested at 
different time points.  
Histological analysis showed that the skeletal muscle repair was enhanced in the absence of A-
SMase (Fig. 4A). Indeed, the analysis of newly formed myofibers in A-SMase-/- and WT mice after 
CTX treatment obtained by counting the centrally nucleated fibers (i.e. fibers with nuclei in the 
center of cytoplasm) showed that the the number of centrally nucleated fibers was enhanced in A-
SMase-/- compared to WT mice at both 5 and 7 days postinjury (Fig. 4B).  
Likewise, we did not found differences between the two types of mice at both 5 and 7 days 
postinjury regarding the CSA of regenerating myofibers (Fig. 4C).  
Interestingly, the expression mRNA levels of MyoD, the early myogenic transcription factor which 
is responsible for myogenic initiation and able to mark proliferating myoblast, were significantly 
higher in A-SMase-/- mice than that in WT mice 3 days after cardiotoxin injury (Fig. 4D). At the 
same time point, also the mRNA expression levels of the late myogenic transcription factor, 
Myogenin, were significantly increased in the absence of A-SMase compared to WT (Fig. 4E). This 
result was further confirmed by western blot analysis (Fig. 4F).  
Taken together these data indicate that the muscle regeneration is accelerated in A-SMase-/- mice.  
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Figure 4: A-SMase affects muscle regeneration  
A) H&E staining on transverse sections of TA muscles treated with CTX  at 1, 3, 5 and 7 days from WT and A-SMase-/- 
mice, 2-month old; (n=2 mice for each experimental time point). Scale Bars, 100µm. B) Quantification of centrally 
nucleated total fibers number carried out on TA muscles at 5 and 7 days after CTX treatment in WT and A-SMase-/- 
mice. For quantification, 5 images per experiment across 3 independent experiments (n=15 images) were analyzed by 
Image J software. Values are expressed as mean ± SEM. Asterisks indicate statistically significant difference between 
WT and A-SMase-/-  mice at each time point considered (*p=<0.05). C) CSA of TA muscle fibers, at 5 and 7 days after 
CTX damage were measured by using Image J based on H&E staining. Data are shown as mean value of CSA of the 
two types of mice. Four animals of each genotype and at least 500 fibers for each animal were measured. D-E) 
RTqPCR analysis of muscle transcription factors MyoD and Myogenin in untreated and CTX treated TA muscles (at 1 
and 3 days) from WT and A-SMase-/- mice.Values are expressed as mean ± SEM (n=8 per group). F) Representative 
western blot of Myogenin protein in CTX treated TA muscles from WT and A-SMase-/- mice (untreated TA used as 
control). GAPDH used as loading control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
58 
 
 
Macrophage infiltration at the injury site is increased in A-SMase-/- compared to WT mice 
 
The skeletal muscle regeneration process is realized through the activation, proliferation and 
differentiation of muscle progenitor cells. Since in vitro analysis revealed no differences in muscle 
satellite cells derived from A-SMase-/- and WT mice in terms of number, proliferation and 
differentiation ability, we hypothesized that after muscle injury, the muscle niche of A-SMase-/- 
mice might be different from that WT and thus influences the muscle progenitor cells response to 
muscle damage. 
First, to test this hypothesis we assessed the number of satellite cells in TA of A-SMase-/- and WT 
mice post CTX injury. Flow Cytometry analysis showed that the number of satellite cells 
significantly increased in A-SMase-/- mice at 1 and 3 days after damage in comparison to WT mice 
(Fig. 5A).  
Since inflammatory cells and their extrinsic factors play a significant role in the local environment 
at the injury site, we investigated whether A-SMase might be involved in the signaling of immune 
response which naturally occurs after muscle damage.  
We thus assessed the macrophages infiltration occuring after CTX injury. By Flow Cytometry 
analysis we found a higher number of macrophages (CD45+/F4/80+ positive cells) infiltrating the 
damaged muscle of A-SMase-/- compared to WT mice at 1, 3, and 5 days after injury (Fig. 5B).  
This data was further confirmed by RTqPCR analysis of F4/80 and of cytokines involved in the 
recruitment of inflammatory cells to the injured site. After day 1 of CTX damage we found that 
F4/80, MCP-1, CCL7 and CCR2 were significantly higher in A-SMase-/- mice compared to WT 
(Fig. 5C). 
This evidence suggests that the enhanced regeneration in A-SMase-/- mice should be due to a 
definite niche at the damaged site, strongly influenced by the presence or absence of A-SMase 
which could be the key factor determining the speed of regeneration.  
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Figure 5: Macrophage infiltration at the injury site is increased in A-SMase-/- compared to WT mice 
A) The graph shows the percentage (%) of satellite cells number (α7+cells) in TA from WT and A-SMase-/- mice 
measured by Flow Cytometry after 1 and 3 days of CTX treatment. B) Percentage (%) of CD45+/F4/80+ positive cells 
measured by Flow Cytometry in untreated and treated TA muscles with CTX from WT and A-SMase-/- mice at 1, 3 and 
5 days..  C) RTqPCR analysis of F4/80 (fold induction), MCP-1, CCL7 and CCR2 on mRNA extracted from TA of WT 
and A-SMase-/- mice after 1 day of CTX treatment. Values are expressed as mean ± SEM (n=8 per group). Asterisks 
indicate statistically significant difference between WT and A-SMase-/- mice at each time point considered (*p<0.05). 
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Anti-inflammatory cytokines expression is enhanced in A-SMase-/-mice after cardiotoxin 
injury  
 
Inflammatory reaction plays a key role in satellite cells activation and proliferation in injured 
muscle. Thus we measured the pro- and anti-inflammatory cytokines profile of TA from WT and A-
SMase-/- mice after CTX injection. 
We did not found any significant difference in the expression levels of the pro-inflammatory 
cytokine TNF-α between WT and A-SMase-/- mice, noteworthy, the pro-inflammatory cytokine IL-
1β was present in lower levels over time in A-SMase-/- mice after CTX injury compared to WT, 
suggesting an enhanced clearence of M1-type pro-inflammatory macrophages at the injured site 
(Fig. 6A).  
Contrariwise, 1 and 3 days after CTX injection, the anti-inflammatory cytokines IL-10 and TGF-β, 
showed significantly higher expression levels in A-SMase-/- when compared to WT mice, 
suggesting an enhanced activation of M2-type anti-inflammatory macrophages (Fig. 6B).  
Interestingly, Insulin-like growth factor 1 (IGF-1), a well-known growth factor and a potent 
enhancer of tissue regeneration, showed much higher expression levels in A-SMase-/- mice 
compared to WT, at each time point from day 1 to 7 after CTX injury (Fig. 6C). This is a relevant 
finding since IGF-1 is able to promotes the proliferation and differentiation of myoblasts and its 
over expression in muscle injury leads to faster resolution of the inflammatory phase (Tonkin et al., 
2015). 
These results suggest that the switch from pro- to anti-inflammatory macrophages is enhanced in A-
SMase-/- mice after muscle damage and so this might be an explanation of our data demonstrating 
that the absence of A-SMase leads to an accelerated regeneration after CTX injury.  
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Figure 6: Anti-inflammatory cytokines expression is enhanced in A-SMase-/- mice after cardiotoxin injury  
 
A) RTqPCR analysis of TNF-α  and IL-1β on mRNA extracted from TA of WT and A-SMase-/- mice after 1, 3 and 7 
days of CTX treatment. Values are expressed as mean ± SEM (n=8 per group) *p<0.05. B) RTqPCR analysis of IL-10 
and TGF-β on mRNA extracted from TA of WT and A-SMase-/- mice after 1, 3 and 7 days of CTX treatment. Values 
are expressed as mean ± SEM (n=8 per group) ) *p<0.05. C) RTqPCR analysis of IGF-1 on mRNA extracted from TA 
of WT and A-SMase-/- mice after 1, 3, 5 and 7 days of CTX treatment. Values are expressed as mean ± SEM (n=8 per 
group) *p<0.05. Asterisks indicate statistically significant difference between WT and A-SMase-/- mice at each time 
point considered. For each graph the UT indicates the untreated state of TA muscle analyzed.  
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A-SMase-/- mice show an altered balance between pro- and anti-inflammatory macrophages 
after muscle damage 
 
To understand whether the balance between pro- and anti-inflammatory macrophages could be 
altered by A-SMase expression after muscle injury, we examined and quantified by Flow 
Cytometry both M1 and M2 macrophage types from the first day after CTX injection in TA of A-
SMase-/- and WT mice. 
As cell surface markers for M1 and M2 macrophages we used CD80 and CD206, respectively.  
At day 1 and 3 after muscle injury, we found that the distribution of the two macrophage subsets 
was altered in A-SMase-/- regenerating muscle with fewer CD80-positive macrophages in 
comparison to WT muscle. Accordingly, the M1/M2 ratio indicates that the M1 macrophage 
proportion was significantly lower in the absence of A-SMase compared to WT (Fig. 7A). This 
finding indicates a short M1 phenotype retention phase and corresponding enhanced M2 activation 
in A-SMase-/- mice.  
Thus, in order to confirm the role of A-SMase in the alteration of macrophage subsets balance in 
muscle we analyzed the polarization to M1/M2 macrophages, in vitro. To this end, bone marrow 
derived macrophages (BMDM) from WT and A-SMase-/- mice were treated with different cytokines 
in order to trigger various pro-inflammatory and anti-inflammatory profiles: IFN-γ treatment has 
been used to elicited M1 pro-inflammatory macrophages, IL-4 and IL-10 have been used to 
stimulate the anti-inflammatory M2 state. By RTqPCR we analyzed genes normally expressed by 
M1 subsets such as CD80, iNOS and IL-1β and by M2 types such as CD206, Arginase1 and 
CD163. The results show that A-SMase-/- M1 macrophages have a significantly lower expression 
levels of transcripts that normally are elevated in M1 macrophages (CD80, iNOS, IL-1β) in 
comparison to M1 population of WT. Conversely, A-SMase-/- M2 macrophages showed no 
differences compared to WT macrophages (Fig. 7B). 
Together, our findings indicate that after muscle injury the number of M1 macrophages is lower in 
the absence of A-SMase compared to WT; furthermore, our in vitro results indicate that A-SMase is 
fundamental for M1 macrophage polarization since its absence leads to an impairment in the 
expression of M1 macrophage markers. 
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Figure 7: A-SMase-/- mice show an altered balance between pro- and anti-inflammatory macrophages after 
muscle damage 
 
A) The graph shows the ratio of M1/M2 macrophages in TA from WT and A-SMase-/- mice measured by Flow 
Cytometry analysis after 1 and 3 days of CTX treatment (n=4 per group). B) Left panel: RTqPCR analysis of M1 
macrophage markers, CD80, iNOS and IL-1β on mRNA extracted from bone marrow derived macrophages polarized to 
M1 macrophages of WT and A-SMase-/- mice. Right panel: RTqPCR analysis of M2 macrophage markers CD206, 
Arginase1 and CD163 on mRNA extracted from bone marrow derived macrophages polarized to M2 phenotype, of WT 
and A-SMase-/- mice. Values are expressed as mean ± SEM (n=4 per group). Asterisks indicate statistically significant 
difference between WT and A-SMase-/- mice (*p<0.05; **p<0.001). 
 
 
RESULTS 
65 
 
 
A-SMase is over expressed in mdx Tibialis Anterior muscle 
 
We then decided to investigate the functional role of A-SMase in the pathogenesis of Duchenne 
muscular dystrophy (DMD), a disease characterized by a strong activation of components of the 
innate immune system (Rosenberg AS et al., 2015) in order to better understand its involvement in 
the establishment of inflammation during the progression of the disease. To this end, we took 
advantage of the mdx mice, a mouse model for DMD pathology assessing A-SMase expression in 
TA of WT and mdx mice at 4 and 12 weeks of age that represent the stage of peak muscle necrosis 
and muscle regeneration, respectively.  
By RTqPCR analysis we found a significant increase in the mRNA expression of A-SMase in TA 
of mdx mice both at 4 and 12 weeks compared to WT muscles (Fig. 8A). This result was then 
confirmed by immunofluorescence analysis (Fig. 8B). Also the activity of A-SMase was found to 
be higher in in TA of mdx mice both at 4 and 12 weeks of age compared to WT mice (Fig. 8C). 
Taken together, these findings suggest the involvment of the enzyme A-SMase in the pathogenesis 
of DMD. 
Interestingly, we found that the increase of A-SMase in expression and in activity, paralleled with 
the increase of muscle inflammatory state. To test this evidence, we used CD45 as a marker to 
identify the activated inflammatory cells in TA muscles of WT and mdx mice at 4 and 12 weeks. By 
immunofluorescence staining we detected a higher number of CD45+ positive cells in TA of mdx 
mice both at 4 and 12 weeks of age compared to WT (Fig. 8D). The muscle inflammatory state was 
also assessed by RTqPCR in order to evaluate the mRNA expression of inflammatory cytokines 
such as IL-6, IL-1β and TNF-α. Both mdx TA muscles at 4 and 12 weeks showed a significant 
increase in the mRNA expression of the all inflammatory cytokines compared to WT muscles. (Fig. 
8E). These data were confirmed by Nonspecific Esterase (NSE) staining that depicted 
myophagocytosis: we observed the presence of macrophage activity in regions of mdx TA sections 
both at 4 and 12 weeks of age, completely absent in TA of WT muscles (Fig. 8F).  
No relation was found between A-SMase expression/activity and fibrosis. The fibrosis state 
evaluated by the Masson’s Trichrome staining reveals traces of collagen and interstitial fibrosis in 
TA of both mice at 4 and 12 weeks of age (Fig. 8F).  
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Figure 8: A-SMase is over expressed in mdx Tibialis Anterior muscle  
 
A) RTqPCR analysis of A-SMase expression in TA of WT and mdx mice at 4 and 12 weeks of age. Values are 
expressed as mean ± SEM (n=4 per group) *p<0.05; **p<0.001. B) Immunofluorescence staining of A-SMase 
expression in muscle fibers of TA from WT and mdx mice at 4 and 12 weeks of age. Scale bars, 50µm. C) A-SMase 
activity (U/ML) detected by colorimetric assay and GraphPad software for quantification. The detection was carried out 
on 2 independent experiments with 3 animals per each time point (n=24 animals). D) Quantification of CD45+ positive 
cells in TA muscles of WT and mdx mice both at 4 and 12 weeks analyzed by Image J software (n=3 per each 
genotype). E) RTqPCR analysis of inflammatory cytokines IL-6, IL-1β and TNF-α on mRNA extracted from TA 
muscles of WT and mdx mice both at 4 and 12 weeks of age. Asterisks indicate statistically significant difference 
between WT and mdx mice; *p<0.05; **p<0.001. F) NSE and Masson’s Trichrome stainings on transverse sections of 
TA muscles from WT and mdx mice at 4 weeks (left panel) and 12 weeks of age (right panel) (n=3 mice per each 
genotype). Scale bars, 100µm. 
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A-SMase is over expressed in mdx Diaphragm muscle 
 
The diaphragm of mdx mouse undergoes a progressive degeneration and impairment in structure 
and function that reproduce the degenerative changes of Duchenne Muscular Dystrophy (Stedman 
et al., 1991; Lynch et al 2001). Therefore, we decide to explore the A-SMase expression in 
diaphragm of old mdx and WT mice at 12 weeks of age.  
By immunofluorescence analysis, we found that at 12 weeks of age, A-SMase is mainly distributed 
at muscle fiber periphery in mdx mice by suggesting a translocation of the enzyme to the 
sarcolemma where it is able to produce ceramide from sphingomyelin degradation (Fig. 9A). As the 
translocation of A-SMase is usually associated to an increase of the enzyme activity, we detected 
also A-SMase activity in diaphragm of old mdx and WT mice at 12 weeks of age. The colorimetric 
assay for A-SMase indicated a significantly increased of the enzyme activity in mdx diaphragm 
when compared to that of the WT mice (Fig. 9B). Thus, as for the TA, also for the diaphragm we 
investigated the muscle inflammatory state by using CD45 as marker and NSE staining. We 
observed a higher number of CD45+ positive cells in mdx mice than in WT and regions of 
myophagocytosis/inflammation in mdx diaphragm at both 4 and 12 weeks of age (Fig. 9C-D). These 
findings agree with the above data carried out on mdx TA muscles in which we found that the 
increase of A-SMase is related to the increase of the muscle inflammatory state.  
Also in diaphragm, we did not found any relation between A-SMase expression/activity and 
fibrosis. The Masson’s Trichrome revealed the presence of collagen and interstitial fibrosis in 
diaphragm of mdx mice but not in diaphragm of WT animals at both 4 and 12 weeks of age (Fig. 
9D).  
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Figure 9: A-SMase is over expressed in mdx Diaphragm muscle 
 
A) Immunofluorescence staining of A-SMase (red) expression in muscle fibers of diaphragm from WT and mdx mice at 
12 weeks of age; nuclei were stained with DAPI (blu). Images are representative of immunofluorescence performed in 
muscles from n=3 mice per each genotype. Scale bars, 50 µm. B) A-SMase activity (U/ML) in diaphragm of WT and 
mdx mice at 12 weeks of age detected by colorimetric assay and GraphPad software for quantification. The detection 
was carried out on 2 independent experiments with 3 animals per each genotype (n=12 animals). Asterisks indicate 
statistically significant difference between WT and mdx mice, **p<0.001. C) Quantification of CD45+ positive cells in 
diaphragm of WT and mdx mice at 4 and 12 weeks of age analyzed by Image J software (n=3 mice per each genotype) 
D) NSE and Masson’s Trichrome stainings on diaphragm from WT and mdx mice at 4 weeks (left panel) and 12 weeks 
of age (right panel) (n=3 mice per each genotype). Scale bars, 100µm. 
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A-SMase activity is over expressed in mdx immune and macrophage derived cell populations 
 
Muscle regeneration is a complex process characterized by a synchronized cross-talk between 
skeletal muscle and immune cells (Pillon et al.,2012). Neverthless, dystrophic muscle undergoes to 
an irregular interaction between muscle cells and immune system so that we wondered whether A-
SMase might have a role in the balance of this cross-talk and hence in the DMD pathogenesis.  
For this reason, we assessed A-SMase expression and activity in muscle and immune system-
derived cells from mdx and WT at both the necrosis peak (4 weeks) and at the regeneration phase 
(12 weeks).  
By magnetic separation we isolated muscular and immune cells from muscles of both mdx and WT 
mice. Thus, immune cells, identified as CD45+ positive cells, were analyzed by RTqPCR finding 
that in mdx mice they showed a higher positivity for F4/80, CD86 and CD206 macrophage markers, 
compared to those found in WT muscles (Fig. 10A). Moreover, as expected, we observed that while 
the M1 marker CD86 was highly expressed in mdx at 4 weeks of age and then returns to level 
similar to that of WT at 12 weeks, in line with necrotic phase of DMD, the M2 marker CD206 was 
always increased in mdx, with a much higher expression at 12 weeks of age, consistently with the 
regenerative phase of DMD (Fig. 10A).  
Then, A-SMase expression/activity were evaluated in immune and muscular cells in dystrophic 
context. So, immune system cell (CD45+) and muscle derived cell (CD45-) populations were 
analyzed by RTqPCR. A-SMase expression and activity were significantly higher in mdx immune 
cells at 1 month of age compared to WT (Fig. 10B-C); this event paralleled with the increased M1 
macrophages (Fig. 10A) that we demonstrated being dependent on A-SMase expression (Fig. 7B). 
Moreover, A-SMase activity was found to be significantly increased in muscle cells of mdx mice in 
comparison to WT at 4 weeks of age (Fig. 10C).  
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Figure 10: A-SMase activity is over expressed in mdx immune and macrophage derived cell populations  
 
A) RTqPCR analysis of immune system cells (CD45+) for macrophage markers F4/80, CD86 and CD206 in mdx and 
WT mice at 4 and 12 weeks of age. Values are expressed as mean ± SEM (n= 5 per each group). B) RTqPCR analysis 
of immune system (CD45+) and muscular cells (CD45-) for A-SMase expression (Smpd1 gene) in mdx and WT mice at 
4 and 12 weeks of age. Values are expressed as mean ± SEM (n=5 per each group). C) A-SMase activity (U/ML) 
measured in immune system (CD45+) and muscular cells (CD45-) by colorimetric assay and GraphPad software for 
quantification in mdx and WT mice at 4 and 12 weeks of age (n=3 per each group). Asterisks indicate statistically 
significant difference between WT and mdx mice, *p<0.05; **p<0.001.  
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Naproxcinod significantly decreases A-SMase expression and activity in Tibialis Anterior of 
mdx mice  
Since our results showed that the increase of A-SMase in expression and activity paralleled with the 
increase of muscle inflammatory state (Fig.8D-9C) we evaluated the expression and the activity of 
the enzyme in TA of mdx mice after long-term treatment (6 months) with the anti-inflammatory 
drug Naproxcinod, starting at 1 month of age.  
Naproxcinod has both anti-inflammatory and analgesic effects (Schintzer et al., 2005). The effects 
of Naproxcinod have been investigated on the mdx skeletal muscle. Uaesoontrachoon et al., 
demonstrated that Naproxcinod-treated mdx mice showed a significant reduction of inflammation in 
both fore- and hind limb muscles.  
After 6 months, we found that TA of Naproxcinod-treated mdx mice showed the mRNA expression 
levels of A-SMase significantly decreased compared to vehicle-treated mdx animals (Fig. 11A). 
More importantly, we also found that in TA, Naproxcinod significantly reduced A-SMase activity 
compared to vehicle-treated mdx mice (Fig. 11B).  
This finding corroborates our previous results in which we demonstrated a strong connection 
between A-SMase increase in expression/activity and muscle inflammatory state observed in a 
chronic damage such as that DMD.  
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Figure 11: Naproxcinod significantly decreases A-SMase expression and activity in Tibialis Anterior of mdx 
mice.  
 
A) RTqPCR analysis of A-SMase expression (Smpd1 gene) in mdx-vehicle and and mdx-treated with Naproxcinod. 
Values are expressed as mean ± SEM (n=5 per each group). B) A-SMase activity (a.u) measured in mdx vehicle and 
mdx treated with Naproxcinod by colorimetric assay and GraphPad software for quantification (n=5 per each group). 
Asterisks indicate statistically significant difference between mdx-vehicle and mdx-Naproxcinod-treated mice (*p<0.05, 
**p<0.01). C) Immunofluorescence staining of A-SMase (red) expression in muscle fibers of TA from mdx-vehicle and 
and mdx-treated with Naproxcinod; nuclei were stained with DAPI (blu); in green CD45+ positive cells. Images are 
representative of immunofluorescence performed in muscles from n=5 mice per each group. Scale bars, 100 µm. 
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DISCUSSION 
 
In the present study, we investigated, for the first time, the functional role of the sphingolipid 
metabolizing-enzyme A-SMase in the pathophysiology of acute and chronic muscle damage both 
characterized by the activation of the immune system and by a strong inflammatory status. A-
SMase is a critical mediator of cell signaling since it is able to generate ceramide from the 
membrane lipid sphingomyelin modulating membrane fluidity, which is determinant in triggering 
many cellular processes such as inflammatory pathways. Several studies reported the strong relation 
between high levels of A-SMase expression and inflammatory-associated disorders such as 
Alzheimer’s, Parkinson’s diseases and atherosclerosis (Haughey, 2010; Opreanu et al., 2011; 
Devlin et al., 2008). 
 
A-SMase in acute muscle damage 
Our results reveal an up regulation of A-SMase expression upon cardiotoxin (CTX)-induced acute 
damage in Tibialis Anterior (TA) of WT mice that implies its involvement in muscle 
inflammation/regeneration. Taking advantage of A-SMase -/- mice, we demonstrated that A-SMase 
is important in regulating skeletal muscle regeneration following acute muscle damage. As regard 
the skeletal muscle morphology of WT and A-SMase-/- mice before injury, no difference were found 
between the two murine models. This finding reveals that the loss of A-SMase does not affect the 
normal skeletal muscle development.  
Skeletal muscle has a great capacity to regenerate new muscle fibers after severe damage (Tedesco 
et al., 2010). This regenerative capacity relies on muscle progenitor cells, namely, SCs. As SCs are 
able to proliferate and differentiate in response to injury, we investigated whether the absence of A-
SMase could affect these two capacities of muscle progenitor cells. The assessment of SC 
populations in vivo and in vitro isolated from WT and A-SMase-/- mice before injury did not reveal 
differences both in terms of percentage inside the muscle and in terms of proliferation and 
differentiation ability. We hypothesized that after muscle injury the muscle niche of A-SMase-/- 
mice might be different from that of WT and thus could influence the muscle progenitor cells 
response to muscle damage. The analysis of SCs in TA of A-SMase-/- and WT mice post CTX 
injury, showed a significant increase in SCs number in A-SMase-/- mice compared to WT at 1 and 3 
days after damage. This increase in SCs paralleled with an enhanced muscle repair upon acute 
muscle injury. After muscle damage, myofibers undergo degeneration and regeneration (Gao et al., 
2012) events. At 5 and 7 days post-injury, more regenerating myofibers were found in A-SMase-/- 
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mice than that in WT animals and the early and the late muscle transcription factor, MyoD and 
Myogenin, were much higher in A-SMase-/- mice compared to WT suggesting that the regeneration 
process was accelerated in the A-SMase-/-animals.  
After muscle damage, interactions between resident SC and infiltrating inflammatory cells are 
fundamental to restore tissue homeostasis (Mann et al., 2011). The inflammatory response is a 
coordinated process finely regulated and able to promote an efficient regenerative process. 
Functional inflammation necessitates well-regulated infiltration of inflammatory cells and cytokines 
production. For instance, MCP1 is responsible for the mobilization of macrophages from the bone 
marrow to the blood stream and from the blood to the damaged muscle (Lu et al., 2011). Moreover, 
Insulin-like growth factor 1 (IGF-1), a well-known growth factor, is not only important in the cell 
recruitment to the injured muscle (Mourkioti and Rosenthal, 2005) but it is also considered a potent 
enhancer of tissue regeneration since it is able to modulate specific inflammatory mediators 
accelerating skeletal muscle regeneration (Pelosi et al., 2007).  
The analysis of the immune infiltrate at 1-day post-injury showed that the number of infiltrating 
macrophages was significantly higher in A-SMase-/- mice compared to WT suggesting a possible 
role for the enzyme in the recruitment of inflammatory cells after injury. At the same time, several 
cytokines responsible for the recruitment of inflammatory cells, such as MCP-1, CCL7 and CCR2  
found to be enhanced at the injured site in A-SMase-/- muscle compared to WT. This evidence 
suggests that the differences in muscle regeneration might be due to a definite niche at the damaged 
site, strongly influenced by the presence or absence of A-SMase, which could be the key factor 
determining the speed of regeneration.  
Inflammatory reaction plays a key role in SCs activation, proliferation and differentiation in injured 
muscle through the release of cytokines from inflammatory cells (Charge and Rudnicki, 2004; 
Hawke and Garry, 2001; Philippou et al., 2007). Many cytokine genes are up regulated at the 
inflammatory stage (1-3 days) and at the stage of differentiation into myotubes (5 days) (Hirata et 
al., 2003). The first steps of the inflammatory response are associated with the “classically 
activated” (M1) macrophages, which produce pro-inflammatory cytokines. In contrast, the 
resolution of inflammation is associated with the “alternatively activated” anti-inflammatory (M2) 
macrophages (Xuan et al., 2014). M1 macrophages are activated by T-helper (Th)1 cytokines 
interferon-gamma (IFNγ), tumor necrosis factor-alpha (TNF-α), Lipopolysaccharide (LPS), 
Interleukin-6 (IL-6) and IL-1; M2 cells are induced by exposure to cytokines such as IL-4, IL-13, 
IL-10 (Mantovani et al., 2004). The analysis of the expression levels of pro- and anti-inflammatory 
cytokines in WT and A-SMase-/- mice after injury showed the decrease of IL-1β in A-SMase-/- mice 
compared to WT suggesting an enhanced clearance of M1-type pro-inflammatory macrophages at 
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the injured site. Contrariwise, the anti-inflammatory cytokines, IL-10 and TGF-β, showed 
significantly higher expression levels in A-SMase-/- mice compared to WT suggesting an enhanced 
activation of M2-type anti-inflammatory macrophages. Macrophages control the resolution of 
inflammation through the dynamic transition between M1 and M2 phenotype (Mounier et al., 
2013). Our results suggest that the switch from pro- to anti-inflammatory macrophages is enhanced 
in A-SMase-/- mice after injury. This evidence reveals a novel role for A-SMase in regulating the 
delicate balance between M1 and M2 macrophage phenotypes during skeletal muscle regeneration. 
Indeed, upon muscle injury, we found that the M1 macrophage portion was significantly lower in 
the absence of A-SMase indicating a short M1 phenotype retention phase and corresponding 
enhanced M2 activation in A-SMase-/-mice. This evidence was confirmed by A-SMase-/- 
macrophage polarization in vitro, further demonstrating that in the absence of A-SMase M1 subsets 
have significantly lower expression levels of transcripts that normally are elevated in M1 
macrophages in comparison to M1 population of WT mice. Our in vitro results indicate that A-
SMase can regulate the polarization of macrophages towards an inflammatory M1 phenotype since 
its absence leads to impairment in the expression of M1 macrophage markers. IGF-1, a potent 
enhancer of tissue regeneration, critical for muscle growth and able to promote the proliferation and 
differentiation of SCs (Tonkin et al., 2015), showed a much higher expression in A-SMase-/- mice 
compared to WT, at each time point considered after CTX injection. This is consistent with our 
previous finding that regeneration process was accelerated in A-SMase-/- mice. Overall, our findings 
provide A-SMase as a possible target for modulation of muscle regeneration.  
 
 
A-SMase in chronic muscle damage: data from a model of Duchenne Muscular Dystrophy 
In the second part of this project we investigated the functional role of A-SMase in the pathogenesis 
of DMD, a disease characterized by a strong activation of component of the innate immune system 
(Rosenberg et al., 2015), in order to understand its involvement in the progression of the disease. To 
this end, we took advantage of the mdx mice, a mouse model for DMD. A significant increase of A-
SMase in expression and activity in TA of mdx mice compared to WT, at both 4 and 12 weeks of 
age (necrosis and muscle regenerative peak, respectively) suggesting the involvement of the 
enzyme in the pathogenesis of Duchenne dystrophy.  
Consistent with previous findings, in our study, we found that the increase of A-SMase, paralleled 
with the increase of muscle inflammatory state that was confirmed by the higher levels of 
inflammatory cells (CD45+) and inflammatory cytokines such as IL-6, IL-1β and TNF-α found in 
muscles of mdx mice compared to WT.  
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In DMD pathology, respiratory activity is significantly impaired. It is well known that the 
diaphragm of mdx mouse undergoes a progressive degeneration and impairment in structure and 
function that reproduce the degenerative changes of DMD (Stedman et al., 1991; Lynch et al., 
2000). For these reasons, we decide to explore A-SMase expression in diaphragm of old mdx and 
WT mice at 12 weeks of age.  
The increased activity of A-SMase in diaphragm of mdx mice compared to WT controls at 12 weeks 
of age, paralleled with A-SMase localization at muscle fiber periphery. Indeed, the translocation of 
A-SMase on the periphery of the cells is usually associated to an increase of enzyme activity 
(Perrotta et al., 2010; Perrotta et al., 2018). Also in mdx diaphragm at both 4 and 12 weeks of age, 
inflammation was observed. These findings agree with the data obtained in mdx TA muscles in 
which we found that the increase of A-SMase is related to the increase of the muscle inflammatory 
state. Contrariwise, both in TA and in diaphragm of mdx mice, we did not find relation between the 
increase of A-SMase expression/activity and fibrosis suggesting that A-SMase does not influence 
this event.  
During DMD progression, dystrophic muscle undergoes an irregular interaction between muscle 
cells and immune system. The analysis of mdx muscles showed high levels of M1 marker CD86 at 
4 weeks of age that returns to levels similar to those of WT at 12 weeks of age. The M2 marker, 
CD206, was always increased in mdx with a much higher expression at 12 weeks of age, 
consistently with the regenerative phase of DMD. Consistent with the data about the role of A-
SMase in M1 polarization, A-SMase expression and activity in immune cells (CD45+) derived from 
mice (4 weeks old) was increased in mdx mice compared to WT. Furthermore, we also found a 
significant increase of A-SMase activity in muscle cells (CD45-) of mdx mice in comparison to WT 
at 4  weeks of age.  
Finally, the involvement of A-SMase in skeletal muscle inflammation in DMD has been 
corroborated by the use of anti-inflammatory drug Naproxcinod. Long-term treatment with 
Naproxcinod is able to reduce the inflammatory infiltrates and improve skeletal muscle phenotype 
in the mdx mouse model (Miglietta et al., 2015; Uaesoontrachoon et al., 2014). The analysis of TA 
of mdx Naproxcinod-treated mice showed that A-SMase mRNA expression levels decrease 
compared to vehicle-treated mdx animals. More importantly, Naproxcinod also reduced 
significantly A-SMase activity.  
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Conclusions 
In conclusion, our results revealed the strong relation between A-SMase expression and skeletal 
muscle inflammation upon muscle injury. We provide the first evidence that A-SMase affects 
skeletal muscle regeneration after muscle damage and modulates muscle repair by controlling the 
delicate balance of pro- and anti-inflammatory macrophage activation. Of notice, we demonstrated 
that the A-SMase deficiency leads to a defect in the acquisition of the M1 pro-inflammatory 
macrophages phenotype and to an accelerated skeletal muscle regeneration after acute damage. 
Moreover, the results of this present study also showed the upregulation of A-SMase in mdx 
muscles, implying its involvement in the pathogenesis of DMD with a particular effect on 
inflammation. The active role of A-SMase in regulating macrophage homeostasis makes it a 
potential pharmacological target by raising the possibility that modulation of A-SMase expression 
levels could bring therapeutic benefits in DMD pathology but also in various muscle-wasting 
diseases.  
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